<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55279</article-id><article-id pub-id-type="doi">10.7554/eLife.55279</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-174168"><name><surname>Cupo</surname><given-names>Ryan R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7639-1923</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-141850"><name><surname>Shorter</surname><given-names>James</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5269-8533</contrib-id><email>jshorter@pennmedicine.upenn.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Pharmacology Graduate Group, Perelman School of Medicine at the University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Zoghbi</surname><given-names>Huda Y</given-names></name><role>Senior Editor</role><aff><institution>Texas Children's Hospital</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Berger</surname><given-names>James M</given-names></name><role>Reviewing Editor</role><aff><institution>Johns Hopkins University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>06</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e55279</elocation-id><history><date date-type="received" iso-8601-date="2020-01-19"><day>19</day><month>01</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-06-22"><day>22</day><month>06</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Cupo and Shorter</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Cupo and Shorter</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55279-v2.pdf"/><abstract><p>Cells have evolved specialized protein disaggregases to reverse toxic protein aggregation and restore protein functionality. In nonmetazoan eukaryotes, the AAA+ disaggregase Hsp78 resolubilizes and reactivates proteins in mitochondria. Curiously, metazoa lack Hsp78. Hence, whether metazoan mitochondria reactivate aggregated proteins is unknown. Here, we establish that a mitochondrial AAA+ protein, Skd3 (human ClpB), couples ATP hydrolysis to protein disaggregation and reactivation. The Skd3 ankyrin-repeat domain combines with conserved AAA+ elements to enable stand-alone disaggregase activity. A mitochondrial inner-membrane protease, PARL, removes an autoinhibitory peptide from Skd3 to greatly enhance disaggregase activity. Indeed, PARL-activated Skd3 solubilizes α-synuclein fibrils connected to Parkinson’s disease. Human cells lacking Skd3 exhibit reduced solubility of various mitochondrial proteins, including anti-apoptotic Hax1. Importantly, Skd3 variants linked to 3-methylglutaconic aciduria, a severe mitochondrial disorder, display diminished disaggregase activity (but not always reduced ATPase activity), which predicts disease severity. Thus, Skd3 is a potent protein disaggregase critical for human health.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>disaggregase</kwd><kwd>AAA+ protein</kwd><kwd>protein misfolding</kwd><kwd>Skd3</kwd><kwd>Hsp78</kwd><kwd>Hsp104</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM099836</award-id><principal-award-recipient><name><surname>Shorter</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F31AG060672</award-id><principal-award-recipient><name><surname>Cupo</surname><given-names>Ryan R</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM008275</award-id><principal-award-recipient><name><surname>Cupo</surname><given-names>Ryan R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011643</institution-id><institution>Blavatnik Family Foundation</institution></institution-wrap></funding-source><award-id>Blavatnik Family Foundation Fellowship</award-id><principal-award-recipient><name><surname>Cupo</surname><given-names>Ryan R</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001229</institution-id><institution>Mathers Foundation</institution></institution-wrap></funding-source><award-id>MF-1902-00275</award-id><principal-award-recipient><name><surname>Shorter</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AG061784</award-id><principal-award-recipient><name><surname>Shorter</surname><given-names>James</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Skd3 (human ClpB) is a potent ATP-dependent mitochondrial protein disaggregase that is activated by the rhomboid protease, PARL, and inactivated by MGCA7-linked mutations.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Protein aggregation and aberrant phase transitions are elicited by a variety of cellular stressors and can be highly toxic (<xref ref-type="bibr" rid="bib15">Chuang et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Eisele et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Guo et al., 2019</xref>). To counter this challenge, cells have evolved specialized protein disaggregases to reverse aggregation and restore resolubilized proteins to native structure and function (<xref ref-type="bibr" rid="bib110">Shorter, 2017</xref>; <xref ref-type="bibr" rid="bib113">Shorter and Southworth, 2019</xref>). Indeed, protein disaggregases are conserved across all domains of life, with orthologues of Hsp104, a ring-shaped hexameric AAA+ protein, powering protein disaggregation and reactivation (as opposed to degradation) in eubacteria and nonmetazoan eukaryotes (<xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>; <xref ref-type="bibr" rid="bib41">Goloubinoff et al., 1999</xref>; <xref ref-type="bibr" rid="bib95">Queitsch et al., 2000</xref>; <xref ref-type="bibr" rid="bib108">Shorter, 2008</xref>). In nonmetazoan eukaryotes, Hsp104 functions in the cytoplasm and nucleus (<xref ref-type="bibr" rid="bib86">Parsell et al., 1994</xref>; <xref ref-type="bibr" rid="bib124">Tkach and Glover, 2008</xref>; <xref ref-type="bibr" rid="bib131">Wallace et al., 2015</xref>), whereas the closely-related AAA+ disaggregase, Hsp78, resolubilizes and reactivates proteins in mitochondria (<xref ref-type="bibr" rid="bib58">Krzewska et al., 2001</xref>; <xref ref-type="bibr" rid="bib104">Schmitt et al., 1996</xref>). Curiously, at the evolutionary transition from protozoa to metazoa both Hsp104 and Hsp78 are lost and are subsequently absent from all animal species (<xref ref-type="bibr" rid="bib30">Erives and Fassler, 2015</xref>). This loss of Hsp104 and Hsp78 is perplexing given that toxic protein aggregation remains a major challenge in metazoa (<xref ref-type="bibr" rid="bib28">Eisele et al., 2015</xref>). Indeed, it is even more baffling since ectopic expression of Hsp104 is well tolerated by animal cells and can be neuroprotective in animal models of neurodegenerative disease (<xref ref-type="bibr" rid="bib22">Cushman-Nick et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Dandoy-Dron et al., 2006</xref>; <xref ref-type="bibr" rid="bib50">Jackrel et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Lo Bianco et al., 2008</xref>; <xref ref-type="bibr" rid="bib91">Perrin et al., 2007</xref>; <xref ref-type="bibr" rid="bib100">Satyal et al., 2000</xref>; <xref ref-type="bibr" rid="bib128">Vacher et al., 2005</xref>; <xref ref-type="bibr" rid="bib138">Yasuda et al., 2017</xref>).</p><p>Metazoa may partially compensate for the absence of Hsp104 activity in the cytoplasm and nucleus with alternative general protein-disaggregase systems, such as Hsp110, Hsp70, Hsp40, and small heat-shock proteins (<xref ref-type="bibr" rid="bib27">Duennwald et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Mattoo et al., 2013</xref>; <xref ref-type="bibr" rid="bib84">Nillegoda et al., 2015</xref>; <xref ref-type="bibr" rid="bib106">Scior et al., 2018</xref>; <xref ref-type="bibr" rid="bib109">Shorter, 2011</xref>; <xref ref-type="bibr" rid="bib110">Shorter, 2017</xref>; <xref ref-type="bibr" rid="bib126">Torrente and Shorter, 2013</xref>) as well as client-specific disaggregases in the cytoplasm such as nuclear-import receptors (<xref ref-type="bibr" rid="bib44">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Guo et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Niaki et al., 2020</xref>; <xref ref-type="bibr" rid="bib140">Yoshizawa et al., 2018</xref>). However, Hsp110 is not found in mitochondria (<xref ref-type="bibr" rid="bib130">Voos and Röttgers, 2002</xref>). Thus, it continues to remain uncertain whether, in the absence of Hsp78, metazoan mitochondria harbor a disaggregase that solubilizes and reactivates aggregated proteins.</p><p>Here, we investigate whether Skd3 (encoded by human <italic>CLPB</italic>) might act as a mitochondrial protein disaggregase in metazoa (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). Skd3 is a ubiquitously expressed, mitochondrial AAA+ protein of poorly-defined function, which is related to Hsp104 and Hsp78 via its HCLR clade AAA+ domain (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib31">Erzberger and Berger, 2006</xref>; <xref ref-type="bibr" rid="bib89">Périer et al., 1995</xref>; <xref ref-type="bibr" rid="bib107">Seraphim and Houry, 2020</xref>). Skd3 appears to play an important role in maintaining mitochondrial structure and function (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). Curiously, Skd3 first appears in evolution alongside Hsp104 and Hsp78 in choanoflagellates, a group of free-living unicellular and colonial flagellate eukaryotes that are the closest extant protozoan relatives of animals (<xref ref-type="fig" rid="fig1">Figure 1b</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <xref ref-type="bibr" rid="bib8">Brunet and King, 2017</xref>; <xref ref-type="bibr" rid="bib30">Erives and Fassler, 2015</xref>). During the complex evolutionary transition from protozoa to metazoa, Skd3 is retained, whereas Hsp104 and Hsp78 are lost (<xref ref-type="bibr" rid="bib30">Erives and Fassler, 2015</xref>). Indeed, Skd3 is conserved in many metazoan lineages (<xref ref-type="fig" rid="fig1">Figure 1a,b</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <xref ref-type="bibr" rid="bib30">Erives and Fassler, 2015</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Skd3 is homologous to Hsp104 and Hsp78 and is conserved across diverse metazoan lineages.</title><p>(<bold>A</bold>) Domain map depicting <italic>S. cerevisiae</italic> Hsp104, <italic>S. cerevisiae</italic> Hsp78, and <italic>H. sapiens</italic> Skd3. Hsp104 is composed of a N-terminal domain (NTD), nucleotide-binding domain 1 (NBD1), middle domain (MD), nucleotide-binding domain 2 (NBD2), and C-terminal domain (CTD). Hsp78 is composed of a mitochondrial-targeting signal (MTS), NBD1, MD, NBD2, and CTD. Skd3 is composed of a MTS, a short hydrophobic stretch of unknown function, an ankyrin-repeat domain (ANK) containing four ankyrin repeats, an NBD that is homologous to Hsp104 and Hsp78 NBD2, and a CTD. (<bold>B</bold>) Phylogenetic tree depicting a Clustal Omega alignment of Skd3 sequences from divergent metazoan lineages and the protozoan <italic>Monosiga brevicollis</italic>. The alignment shows conservation of Skd3 across diverse species and shows high similarity between mammalian Skd3 proteins.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Skd3 NBD alignment to other AAA+ proteins reveals high similarity to Hsp104 and Hsp78.</title><p>Alignment of the NBD from <italic>H. sapiens</italic> Skd3 and NBD2 from <italic>S. cerevisiae</italic> Hsp104, <italic>S. cerevisiae</italic> Hsp78, <italic>E. coli</italic> ClpB, <italic>E. coli</italic> ClpA, and <italic>S. aureus</italic> ClpC. Alignments were constructed using Clustal Omega. Bottom row shows consensus sequence of alignment. Highlighted in red are the Walker A and Walker B motifs. Highlighted in green are the Pore-Loop motifs. Highlighted in blue are the Sensor I, Sensor II, and Arginine-Finger motifs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Skd3 is comprised of a mitochondrial-targeting signal (MTS), followed by a short hydrophobic stretch, an ankyrin-repeat domain (ANK), an AAA+ nucleotide-binding domain (NBD), and a small C-terminal domain (CTD) (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). The Skd3 NBD closely resembles NBD2 of Hsp104 and Hsp78 (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Aside from this similarity, Skd3 is highly divergent from Hsp104 and Hsp78 (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib126">Torrente and Shorter, 2013</xref>). For example, Skd3, Hsp104, and Hsp78 all have short CTDs, but these are divergent with the Skd3 CTD being basic compared to the more acidic Hsp104 and Hsp78 CTDs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Moreover, the other domains in Hsp104 (N-terminal domain [NTD], NBD1, and middle domain [MD]) and Hsp78 (NBD1 and MD) are not found in Skd3 (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In their place, is an ankyrin-repeat domain (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), which interestingly is an important substrate-binding domain of another protein disaggregase, chloroplast signal recognition particle 43 (cpSRP43) (<xref ref-type="bibr" rid="bib54">Jaru-Ampornpan et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Jaru-Ampornpan et al., 2010</xref>; <xref ref-type="bibr" rid="bib72">McAvoy et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Nguyen et al., 2013</xref>).</p><p>Importantly, mutations in the Skd3 ankyrin-repeat domain and NBD are linked to the rare, but severe mitochondrial disorder, 3-methylglutaconic aciduria, type VII (MGCA7) (<xref ref-type="bibr" rid="bib9">Capo-Chichi et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Kanabus et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Kiykim et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>; <xref ref-type="bibr" rid="bib101">Saunders et al., 2015</xref>; <xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>). MGCA7 is an autosomal recessive metabolic disorder that presents with increased levels of 3-methylglutaconic acid (3-MGA), neurologic deterioration, and neutropenia (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). Typically, patients present with infantile onset of a progressive encephalopathy with movement abnormalities and delayed psychomotor development (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). Other common, but variable, phenotypes include cataracts, seizures, and recurrent infections (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). These issues can be severe with afflicted infants typically only living for a few weeks or months (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). Patients may also present with more moderate phenotypes, including neutropenia, hypotonia, spasticity, movement abnormalities, epilepsy, and intellectual disability (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). Mildly affected individuals have no neurological problems, normal life expectancy, but present with neutropenia (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). There is no cure and no effective therapeutics for severe or moderate forms of MGCA7. Moreover, little is known about how Skd3 mutations might cause disease.</p><p>Collectively, these various observations concerning Skd3 led us to hypothesize that Skd3 is a metazoan mitochondrial protein disaggregase of key importance for mitochondrial proteostasis. We further hypothesized that MGCA7-associated Skd3 mutations would disrupt disaggregase activity. Our investigation of these hypotheses is detailed below. Briefly, we find that Skd3 is an ATP-dependent mitochondrial protein disaggregase that is activated by the rhomboid protease, PARL, and inactivated by MGCA7-linked mutations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Skd3 couples ATP hydrolysis to protein disaggregation and reactivation</title><p>To biochemically dissect the activity of Skd3, we purified full-length Skd3 (see Materials and methods), lacking the mitochondrial targeting signal, which is cleaved by the mitochondrial-processing peptidase (MPP) upon import into mitochondria (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–d</xref>; <xref ref-type="bibr" rid="bib17">Claros and Vincens, 1996</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>). We term this form of Skd3, <sub>MPP</sub>Skd3. We first assessed that ATPase activity of <sub>MPP</sub>Skd3 and found that it is active (<xref ref-type="fig" rid="fig2">Figure 2b</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a</xref>). Indeed, <sub>MPP</sub>Skd3 displayed robust ATPase activity that was comparable to Hsp104 and over two-fold higher than previously reported values for <sub>MPP</sub>Skd3 activity (<xref ref-type="fig" rid="fig2">Figure 2b</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a</xref>; <xref ref-type="bibr" rid="bib81">Mróz et al., 2020</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Skd3 is a protein disaggregase.</title><p>(<bold>A</bold>) Domain map depicting the Mitochondrial-processing peptidase (MPP) cleavage site and mature-length Skd3 (<sub>MPP</sub>Skd3). The MTS was predicted using MitoProt in agreement with previous work, as outlined in the Materials and methods. The positions of the Walker A mutation (K387A) predicted to disrupt ATP binding and hydrolysis, pore-loop tyrosine mutation (Y430A) predicted to disrupt substrate binding, and Walker B mutation (E455Q) predicted to disrupt ATP hydrolysis are shown. (<bold>B</bold>) <sub>MPP</sub>Skd3 is an ATPase. ATPase assay comparing <sub>MPP</sub>Skd3 and Hsp104. <sub>MPP</sub>Skd3 and Hsp104 ATPase were compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>C</bold>) Luciferase disaggregation/reactivation assay showing that <sub>MPP</sub>Skd3 has disaggregase activity in the presence but not absence of ATP. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>D</bold>) ATPase assay comparing <sub>MPP</sub>Skd3, <sub>MPP</sub>Skd3<sup>K387A</sup> (Walker A mutant), <sub>MPP</sub>Skd3<sup>E455Q</sup> (Walker B mutant), and <sub>MPP</sub>Skd3<sup>Y430A</sup> (Pore-Loop mutant), showing that both Walker A and Walker B mutations abolish Skd3 ATPase activity, whereas the Pore Loop mutation reduces ATPase activity. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05, ****p&lt;0.0001). (<bold>E</bold>) Luciferase disaggregation/reactivation assay comparing <sub>MPP</sub>Skd3 to Walker A, Walker B, and Pore-Loop variants demonstrating that ATP binding, ATP hydrolysis, and pore-loop contacts are essential for Skd3 disaggregase activity. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Recombinant Skd3 is highly pure and immunoreactive with several commercially available antibodies.</title><p>(<bold>A</bold>) Representative gel of <sub>MPP</sub>Skd3 showing high purity via Coomassie Brilliant Blue stain. (<bold>B</bold>) Western blot with Skd3 antibody (Abcam ab76179) showing immunoreactivity of a singular band of purified <sub>MPP</sub>Skd3. (<bold>C</bold>) Western blot with Skd3 antibody (Abcam ab87253) showing immunoreactivity of a singular band of purified <sub>MPP</sub>Skd3. (<bold>D</bold>) Western blot with Skd3 antibody (Proteintech #15743–1-AP) showing immunoreactivity of a singular band of purified <sub>MPP</sub>Skd3.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Skd3 is a protein disaggregase.</title><p>(<bold>A</bold>) ATPase assay time course showing that <sub>MPP</sub>Skd3 ATPase activity is approximately linear over the first five minutes of the assay. (N = 4, bars show mean ± SEM). (<bold>B</bold>) Luciferase disaggregation/reactivation activity time course showing that <sub>MPP</sub>Skd3 disaggregates more luciferase over time. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40 (N = 4, bars show mean ± SEM). (<bold>C</bold>) Luciferase disaggregation/reactivation assay showing dose-response relationship between <sub>MPP</sub>Skd3 concentration and luciferase reactivation. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. (N = 4, dots show mean ± SEM, EC<sub>50</sub> = 0.394 μM). (<bold>D</bold>) Luciferase disaggregation/reactivation assay showing <sub>MPP</sub>Skd3 disaggregase activity in the presence of different nucleotides. Results show that <sub>MPP</sub>Skd3 can disaggregate luciferase in the presence of ATP, but not in the absence of ATP, in the presence of ADP, or in the presence of ATP analogues ATPγS (slowly hydrolyzable) or AMP-PNP (non-hydrolyzable). Luciferase assay incubated for 30 min and no ATP regeneration system was used. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40 (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig2-figsupp2-v2.tif"/></fig></fig-group><p>To determine if <sub>MPP</sub>Skd3 is a disaggregase we used a classic aggregated substrate, urea-denatured firefly luciferase aggregates, which form aggregated structures of ∼500–2000 kDa and greater in size that are devoid of luciferase activity (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Indeed, very few luciferase species smaller than ~400 kDa can be detected (<xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Importantly, these samples are devoid of misfolded, monomeric luciferase (<xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Reactivation of luciferase in this assay is thus primarily achieved by the extraction and subsequent refolding of monomeric luciferase (M<sub>w</sub> ~61 kDa) from large aggregated structures (∼500–2,000 kDa or larger) (<xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Hence, in this assay, luciferase reactivation is an accurate proxy for luciferase disaggregation. Importantly, Hsp70 and Hsp40 are unable to disaggregate and reactivate luciferase found in these large aggregated structures (∼500–2,000 kDa or larger) (<xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Indeed, Hsp70 and Hsp40 were unable to recover any active luciferase (~0.05 ± 0.00% [mean ± SEM] native luciferase activity) and were similar to the buffer control (~0.04 ± 0.00% native luciferase activity) (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,d</xref>). As expected, Hsp104 alone was also unable to disaggregate and reactivate luciferase (~0.08 ± 0.01% native luciferase activity) (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,d</xref>; <xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). By contrast, the combination of Hsp104, Hsp70, and Hsp40 recovered ~7.68 ± 0.44% native luciferase activity (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,d</xref>; <xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>). Remarkably, <sub>MPP</sub>Skd3 displayed robust disaggregase activity in the presence of ATP as it was able to recover ~2.87 ± 0.17% native luciferase activity (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,c</xref>). Indeed, <sub>MPP</sub>Skd3 displayed ~40% of the disaggregase activity of Hsp104 plus Hsp70 and Hsp40 under these conditions (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). While Hsp104 required the presence of Hsp70 and Hsp40 to disaggregate luciferase (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,c</xref>; <xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>), <sub>MPP</sub>Skd3 had no requirement for Hsp70 and Hsp40 (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,c</xref>). This finding indicates that <sub>MPP</sub>Skd3 is a ‘stand-alone’ disaggregase.</p><p>Next, we assessed the nucleotide requirements for <sub>MPP</sub>Skd3 disaggregase activity. <sub>MPP</sub>Skd3 disaggregase activity was supported by ATP but not by the absence of nucleotide or the presence of ADP (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,d</xref>). Likewise, neither the non-hydrolyzable ATP analogue, AMP-PNP, nor the slowly hydrolyzable ATP analogue, ATPγS, could support <sub>MPP</sub>Skd3 disaggregase activity (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2b,d</xref>). Collectively, these data suggest that <sub>MPP</sub>Skd3 disaggregase activity requires multiple rounds of rapid ATP binding and hydrolysis, which is similar mechanistically to Hsp104 (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib111">Shorter and Lindquist, 2004</xref>; <xref ref-type="bibr" rid="bib112">Shorter and Lindquist, 2006</xref>).</p><p>We next investigated the role of conserved AAA+ elements in Skd3 activity. Thus, we mutated: (1) a critical lysine in the Walker A motif to alanine (K387A), which is predicted to disrupt ATP binding and hydrolysis (<xref ref-type="bibr" rid="bib45">Hanson and Whiteheart, 2005</xref>; <xref ref-type="bibr" rid="bib107">Seraphim and Houry, 2020</xref>); (2) a critical glutamate in the Walker B motif to glutamine (E455Q), which is predicted to disrupt ATP hydrolysis but not ATP binding (<xref ref-type="bibr" rid="bib45">Hanson and Whiteheart, 2005</xref>; <xref ref-type="bibr" rid="bib107">Seraphim and Houry, 2020</xref>); and (3) a highly-conserved tyrosine in the predicted -GYVG- substrate-binding loop to alanine that is predicted to disrupt substrate binding (Y430A) as in related HCLR clade AAA+ ATPases (<xref ref-type="bibr" rid="bib35">Gates et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Hanson and Whiteheart, 2005</xref>; <xref ref-type="bibr" rid="bib63">Lopez et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Martin et al., 2008</xref>; <xref ref-type="bibr" rid="bib97">Rizo et al., 2019</xref>; <xref ref-type="bibr" rid="bib107">Seraphim and Houry, 2020</xref>). The equivalent Walker A, Walker B, and substrate-binding loop mutations in NBD1 and NBD2 of Hsp104 severely disrupt disaggregase activity (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Lum et al., 2004</xref>; <xref ref-type="bibr" rid="bib125">Torrente et al., 2016</xref>). Likewise, <sub>MPP</sub>Skd3<sup>K387A</sup> (Walker A mutant) and <sub>MPP</sub>Skd3<sup>E455Q</sup> (Walker B mutant) displayed greatly reduced ATPase and disaggregase activity (<xref ref-type="fig" rid="fig2">Figure 2d,e</xref>). Thus, <sub>MPP</sub>Skd3 couples ATP binding and hydrolysis to protein disaggregation.</p><p>Interestingly, the pore-loop variant, <sub>MPP</sub>Skd3<sup>Y430A</sup>, exhibited reduced ATPase activity compared to <sub>MPP</sub>Skd3, but much higher ATPase activity than <sub>MPP</sub>Skd3<sup>K387A</sup> and <sub>MPP</sub>Skd3<sup>E455Q</sup> (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). This reduction in ATPase activity was unexpected as equivalent mutations in Hsp104 do not affect ATPase activity (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Lum et al., 2008</xref>; <xref ref-type="bibr" rid="bib65">Lum et al., 2004</xref>; <xref ref-type="bibr" rid="bib125">Torrente et al., 2016</xref>). <sub>MPP</sub>Skd3<sup>Y430A</sup> was also devoid of disaggregase activity (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). The inhibition of disaggregase activity by Y430A was much more severe than the inhibition of ATPase activity (<xref ref-type="fig" rid="fig2">Figure 2d,e</xref>), which suggests that the pore-loop Y430 might make direct contact with substrate to drive protein disaggregation as in Hsp104 (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Gates et al., 2017</xref>). Thus, the conserved putative substrate-binding tyrosine of the -GYVG- pore-loop is critical for <sub>MPP</sub>Skd3 disaggregase activity.</p></sec><sec id="s2-2"><title>Skd3 disaggregase activity is enhanced by PARL cleavage</title><p>We noticed that Skd3 contains an undefined, 35-amino acid, hydrophobic stretch between the N-terminal MTS and the ankyrin-repeat domain (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Intriguingly, Skd3 is cleaved by the inner-membrane rhomboid protease, PARL, at amino acid 127, between the 35-amino acid, hydrophobic stretch and the ankyrin-repeat domain (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib99">Saita et al., 2017</xref>; <xref ref-type="bibr" rid="bib117">Spinazzi et al., 2019</xref>). Sequence analysis shows that the 35-amino acid, hydrophobic stretch and the PARL-cleavage motif are both highly conserved among mammalian Skd3 orthologues (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>). Thus, we hypothesized that this 35-amino acid, hydrophobic stretch might be auto-inhibitory for Skd3 activity.</p><p>To determine whether PARL cleavage of this 35-amino acid, hydrophobic stretch regulates Skd3 activity, we purified Skd3 without this region (<sub>PARL</sub>Skd3) (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). We found that the absence of the 35-residue stretch that is removed by PARL slightly decreased Skd3 ATPase activity compared to <sub>MPP</sub>Skd3 (<xref ref-type="fig" rid="fig3">Figure 3b</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>). Moreover, we find that <sub>MPP</sub>Skd3 ATPase activity is not stimulated by the model substrate, casein, a classic peptide-stimulator of Hsp104 ATPase activity (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>; <xref ref-type="bibr" rid="bib10">Cashikar et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Gates et al., 2017</xref>). By contrast, <sub>PARL</sub>Skd3 ATPase activity is mildly stimulated by casein (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). This finding indicates that <sub>PARL</sub>Skd3 may interact more effectively with substrates than <sub>MPP</sub>Skd3 due to the removal of the 35-amino acid, hydrophobic stretch.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PARL cleavage enhances Skd3 disaggregase activity.</title><p>(<bold>A</bold>) Domain map depicting <sub>MPP</sub>Skd3 and the PARL cleavage site and corresponding PARL-cleaved Skd3 (<sub>PARL</sub>Skd3). The positions of the Walker A mutation (K387A) predicted to disrupt ATP binding and hydrolysis, pore-loop tyrosine mutation (Y430A) predicted to disrupt substrate binding, and Walker B mutation (E455Q) predicted to disrupt ATP hydrolysis are shown. (<bold>B</bold>) ATPase assay comparing <sub>MPP</sub>Skd3 and <sub>PARL</sub>Skd3. <sub>PARL</sub>Skd3 is catalytically active, but is slightly less active than <sub>MPP</sub>Skd3. <sub>PARL</sub>Skd3 and Hsp104 ATPase were compared to <sub>MPP</sub>Skd3 ATPase using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 6, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05, ****p&lt;0.0001). (<bold>C</bold>) Luciferase disaggregation/reactivation assay comparing <sub>MPP</sub>Skd3 disaggregase activity to <sub>PARL</sub>Skd3. <sub>PARL</sub>Skd3 was over 10-fold more active than <sub>MPP</sub>Skd3. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to <sub>MPP</sub>Skd3 using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 6, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>D</bold>) ATPase assay comparing <sub>PARL</sub>Skd3, <sub>PARL</sub>Skd3<sup>K387A</sup> (Walker A), <sub>PARL</sub>Skd3<sup>E455Q</sup> (Walker B), and <sub>PARL</sub>Skd3<sup>Y430A</sup> (Pore Loop), showing that both Walker A and Walker B mutations abolish Skd3 ATPase activity, whereas the Pore-Loop mutation reduces ATPase activity. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>E</bold>) Luciferase disaggregation/reactivation assay comparing <sub>PARL</sub>Skd3 to Walker A, Walker B, and Pore-Loop variants showing that ATP binding, ATP hydrolysis, and pore-loop contacts are essential for <sub>PARL</sub>Skd3 disaggregase activity. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The auto-inhibitory peptide of Skd3 is hydrophobic.</title><p>(<bold>A</bold>) Kyte-Doolittle hydrophobicity score was calculated for Skd3 using the ExPASy web server (<xref ref-type="bibr" rid="bib59">Kyte and Doolittle, 1982</xref>; <xref ref-type="bibr" rid="bib133">Wilkins et al., 1999</xref>). A positive hydrophobicity score indicates highly hydrophobic regions. Analysis shows a spike in hydrophobicity corresponding to the C-terminal portion of the Skd3 auto-inhibitory peptide (92-126), which is removed by PARL cleavage.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>PARL cleavage of Skd3 enhances Skd3 disaggregase activity.</title><p>(<bold>A</bold>) Sequence logo depicting the conservation of the auto-inhibitory peptide (orange) and PARL-cleavage motif (green) of Skd3. Arrows indicate MPP and PARL cleavage sites. Logo shows a high level of homology suggesting conserved importance. Sequence Logo was built with WebLogo using Skd3 protein sequence from 42 different mammalian species. (<bold>B</bold>) ATPase assay time course showing that <sub>PARL</sub>Skd3 ATPase activity is approximately linear over the first five minutes of the assay (N = 4, bars show mean ± SEM). (<bold>C</bold>) Luciferase disaggregation/reactivation activity time course showing that <sub>PARL</sub>Skd3 disaggregates more luciferase over time. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40 (N = 4, bars show mean ± SEM). (<bold>D</bold>) Luciferase disaggregation/reactivation assay showing dose-response relationship between <sub>PARL</sub>Skd3 concentration and luciferase reactivation. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40 (N = 4, dots show mean ± SEM, EC<sub>50</sub> = 0.836 μM). (<bold>E</bold>) Luciferase disaggregation/reactivation assay showing <sub>PARL</sub>Skd3 disaggregase activity in the presence of different nucleotides. Results show that <sub>PARL</sub>Skd3 can disaggregate luciferase in the presence of ATP, but not in the absence of ATP, in the presence of ADP, or in the presence of ATP analogues ATPγS (slowly hydrolyzable) or AMP-PNP (non-hydrolyzable). Luciferase assay incubated for 30 min and no ATP regeneration system was used. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40 (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title><sub>PARL</sub>Skd3, but not <sub>MPP</sub>Skd3, ATPase activity is stimulated by a model substrate.</title><p>(<bold>A</bold>) ATPase assay showing that <sub>PARL</sub>Skd3 but not <sub>MPP</sub>Skd3 is stimulated by the model substrate β-casein. ATPase activity with substrate was compared to controls without substrate using a two-tailed, unpaired t-test. (N = 4, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig3-figsupp3-v2.tif"/></fig></fig-group><p>Remarkably, the absence of the N-terminal peptide known to be removed by PARL unleashed Skd3 disaggregase activity (<xref ref-type="fig" rid="fig3">Figure 3c</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c,d</xref>). Indeed, <sub>PARL</sub>Skd3 exhibited over 10-fold higher disaggregase activity (~44.06 ± 3.78% native luciferase activity recovered, mean ± SEM) compared to <sub>MPP</sub>Skd3 (~3.10 ± 0.44% native luciferase activity recovered) and over five-fold higher disaggregation activity than Hsp104 plus Hsp70 and Hsp40 (~8.58 ± 1.20% native luciferase activity recovered), despite <sub>PARL</sub>Skd3 having lower ATPase activity when compared to <sub>MPP</sub>Skd3 (<xref ref-type="fig" rid="fig3">Figure 3b,c</xref>, and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b,c,d</xref>). These results suggest that Skd3 disaggregase activity is likely regulated by PARL and that PARL-activated Skd3 is a powerful, stand-alone protein disaggregase with activity comparable to potentiated Hsp104 variants (<xref ref-type="bibr" rid="bib50">Jackrel et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Jackrel and Shorter, 2014</xref>; <xref ref-type="bibr" rid="bib51">Jackrel et al., 2015</xref>; <xref ref-type="bibr" rid="bib122">Tariq et al., 2019</xref>; <xref ref-type="bibr" rid="bib121">Tariq et al., 2018</xref>; <xref ref-type="bibr" rid="bib125">Torrente et al., 2016</xref>).</p><p>As with <sub>MPP</sub>Skd3, we found that <sub>PARL</sub>Skd3 disaggregase activity was supported by ATP, but not in the absence of nucleotide or in the presence of ADP, non-hydrolyzable AMP-PNP, or slowly hydrolyzable ATPγS (<xref ref-type="fig" rid="fig3">Figure 3c</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2e</xref>). Likewise, <sub>PARL</sub>Skd3<sup>K387A</sup> (Walker A mutant) and <sub>PARL</sub>Skd3<sup>E455Q</sup> (Walker B mutant) lacked ATPase and disaggregase activity (<xref ref-type="fig" rid="fig3">Figure 3d,e</xref>), indicating that <sub>PARL</sub>Skd3 couples ATP binding and hydrolysis to protein disaggregation. Curiously, <sub>PARL</sub>Skd3<sup>Y430A</sup> (pore-loop mutant) exhibited a larger reduction in ATPase activity than <sub>MPP</sub>Skd3<sup>Y430A</sup> (<xref ref-type="fig" rid="fig2">Figures 2d</xref> and <xref ref-type="fig" rid="fig3">3d</xref>), indicating that the conserved tyrosine in the conserved putative substrate-binding -GYVG- pore loop impacts ATPase activity in Skd3, whereas it has no effect in Hsp104 (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib125">Torrente et al., 2016</xref>). <sub>PARL</sub>Skd3<sup>Y430A</sup> was devoid of disaggregase activity (<xref ref-type="fig" rid="fig3">Figure 3e</xref>), which could be due to reduced ATPase activity, reduced substrate binding, or both.</p></sec><sec id="s2-3"><title>PARL-activated Skd3 solubilizes α-synuclein fibrils</title><p>Next, we assessed whether <sub>PARL</sub>Skd3 could disassemble a stable amyloid substrate, which makes more stringent demands on a disaggregase (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>). Thus, we turned to α-synuclein fibrils, which are connected to Parkinson’s disease and various synucleinopathies (<xref ref-type="bibr" rid="bib47">Henderson et al., 2019</xref>; <xref ref-type="bibr" rid="bib115">Spillantini et al., 1998a</xref>; <xref ref-type="bibr" rid="bib116">Spillantini et al., 1998b</xref>). We utilized a strain of synthetic α-synuclein fibrils capable of eliciting Parkinson’s disease-like symptoms in mice (<xref ref-type="bibr" rid="bib64">Luk et al., 2012</xref>). We employed samples of preformed α-synuclein fibrils that had completely assembled (i.e. 100% of α-synuclein was in the assembled fibril state) and were devoid of soluble α-synuclein (<xref ref-type="fig" rid="fig4">Figure 4a,b</xref>). Using a sedimentation assay combined with a dot-blot, we found that <sub>PARL</sub>Skd3, but not <sub>MPP</sub>Skd3 (data not shown), disaggregated these disease-causing fibrils in the presence, but not absence of ATP (<xref ref-type="fig" rid="fig4">Figure 4a,b</xref>). Thus, <sub>PARL</sub>Skd3 is a powerful protein disaggregase, which could have applications as a potential therapeutic agent to eliminate disease-causing α-synuclein fibrils that underlie Parkinson’s disease and other synucleinopathies.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Skd3 disaggregates α-synuclein fibrils.</title><p>(<bold>A</bold>) Representative dot blot of α-synuclein disaggregation assay. Blot shows solubilization of α-synuclein fibrils by <sub>PARL</sub>Skd3 in the presence of an ATP regeneration system (ARS), but not in the presence of <sub>PARL</sub>Skd3 or ARS alone. (N = 3). (<bold>B</bold>) Quantification of α-synuclein disaggregation assay showing that <sub>PARL</sub>Skd3 in the presence of an ARS disaggregates α-synuclein fibrils. Results are normalized as fraction in the supernatant relative to the fraction in the supernatant and the pellet. The fraction of α-synuclein in the supernatant was compared to buffer using a repeated measure one-way ANOVA and a Dunnett’s multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig4-v2.tif"/></fig></sec><sec id="s2-4"><title>Skd3 disaggregase activity requires the ankyrin-repeat domain and NBD</title><p>To further investigate the mechanism of Skd3 disaggregase activity, we purified the isolated ankyrin-repeat domain and NBD as separate proteins (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Neither the isolated ankyrin-repeat domain nor the isolated NBD exhibited ATPase activity or disaggregase activity (<xref ref-type="fig" rid="fig5">Figure 5b,c</xref>). The lack of ATPase activity and disaggregase activity of the isolated NBD is consistent with a similar lack of activity of isolated NBD2 from Hsp104 or bacterial ClpB and is likely attributed to a lack of hexamer formation, as is observed for ClpB NBD2 (<xref ref-type="bibr" rid="bib6">Beinker et al., 2005</xref>; <xref ref-type="bibr" rid="bib46">Hattendorf and Lindquist, 2002</xref>; <xref ref-type="bibr" rid="bib79">Mogk et al., 2003</xref>). Thus, the ankyrin-repeat domain and NBD combine in <italic>cis</italic> to enable Skd3 ATPase activity and disaggregase activity. We also tested whether the two domains could combine in <italic>trans</italic> as two separate proteins to yield an active ATPase or disaggregase. However, we found that equimolar amounts of the ankyrin-repeat domain and NBD were also inactive (<xref ref-type="fig" rid="fig5">Figure 5b,c</xref>). Thus, Skd3 is unlike bacterial ClpB, which can be reconstituted in <italic>trans</italic> by separate NTD-NBD1-MD and NBD2 proteins (<xref ref-type="bibr" rid="bib6">Beinker et al., 2005</xref>). These findings suggest that the covalent linkage of the ankyrin-repeat domain and NBD is critical for forming a functional ATPase and disaggregase. Importantly, they also predict that truncated MGCA7-linked Skd3 variants, such as R250* and K321* (where * indicates a stop codon), which lack the NBD would be inactive for protein disaggregation and indeed any ATPase-dependent activities.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The ankyrin-repeat domain and NBD are required for Skd3 disaggregase activity.</title><p>(<bold>A</bold>) Domain maps showing the Skd3<sub>ANK</sub> and Skd3<sub>NBD</sub> constructs. (<bold>B</bold>) ATPase assay comparing Skd3<sub>ANK</sub> and Skd3<sub>NBD</sub> ATPase activity. Results show that Skd3<sub>ANK</sub>, Skd3<sub>NBD</sub>, and Skd3<sub>ANK</sub> + Skd3<sub>NBD</sub> do not have ATPase activity. Data are from the same experiments as <xref ref-type="fig" rid="fig3">Figure 3B</xref>. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>C</bold>) Luciferase disaggregation/reactivation assay comparing Skd3<sub>ANK</sub>, Skd3<sub>NBD</sub>, and Skd3<sub>ANK</sub> + Skd3<sub>NBD</sub> d activity. Results show that Skd3<sub>ANK</sub>, Skd3<sub>NBD</sub>, or Skd3<sub>ANK</sub> + Skd3<sub>NBD</sub> are inactive disaggregases. Data are from same experiments as <xref ref-type="fig" rid="fig3">Figure 3C</xref>. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Luciferase disaggregase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig5-v2.tif"/></fig></sec><sec id="s2-5"><title>Skd3 disaggregase activity is not stimulated by Hsp70 and Hsp40</title><p>Hsp104 and Hsp78 collaborate with Hsp70 and Hsp40 to disaggregate many substrates (<xref ref-type="fig" rid="fig2">Figures 2c,e</xref> and <xref ref-type="fig" rid="fig3">3c,e</xref>; <xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Glover and Lindquist, 1998</xref>; <xref ref-type="bibr" rid="bib58">Krzewska et al., 2001</xref>). By contrast, Skd3 does not require Hsp70 and Hsp40 for protein disaggregation (<xref ref-type="fig" rid="fig2">Figures 2c,e</xref>, <xref ref-type="fig" rid="fig3">3c,e</xref> and <xref ref-type="fig" rid="fig4">4a,b</xref>). This finding is consistent with Skd3 lacking the NTD, NBD1, and MD of Hsp104, which interact with Hsp70 (<xref ref-type="bibr" rid="bib25">DeSantis et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Lee et al., 2013</xref>; <xref ref-type="bibr" rid="bib118">Sweeny et al., 2015</xref>; <xref ref-type="bibr" rid="bib119">Sweeny et al., 2020</xref>). Nonetheless, Hsp70 and Hsp40 might still augment Skd3 disaggregase activity. Thus, we tested if Hsp70 and Hsp40 could stimulate Skd3 disaggregase activity. However, neither <sub>MPP</sub>Skd3 nor <sub>PARL</sub>Skd3disaggregase activity was stimulated by Hsp70 and Hsp40 (<xref ref-type="fig" rid="fig6">Figure 6a,b</xref>). Thus, Skd3 is a stand-alone disaggregase that works independently of the Hsp70 chaperone system.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Skd3 does not collaborate with Hsp70 and Hsp40 in protein disaggregation.</title><p>(<bold>A</bold>) Luciferase disaggregation/reactivation comparing <sub>MPP</sub>Skd3 disaggregase activity in the presence or absence of Hsp70 (Hsc70) and Hsp40 (Hdj1). Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Results show a stimulation of Hsp104 disaggregase activity by Hsp70 and Hsp40, but no stimulation of disaggregase activity for <sub>MPP</sub>Skd3. <sub>MPP</sub>Skd3 plus Hsp70 and Hsp40 was compared to <sub>MPP</sub>Skd3 using a two-tailed, unpaired t-test. Test found no significant difference in disaggregation activity. (N = 4, individual data points shown as dots, bars show mean ± SEM). (<bold>B</bold>) Luciferase disaggregation/reactivation comparing <sub>PARL</sub>Skd3 disaggregase activity in the presence or absence of Hsp70 and Hsp40. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Results show no stimulation of disaggregase activity for <sub>PARL</sub>Skd3 by Hsp70 and Hsp40. <sub>PARL</sub>Skd3 plus Hsp70 and Hsp40 was compared to <sub>PARL</sub>Skd3 using a two-tailed, unpaired t-test. Test found no significant difference in disaggregation activity. (N = 4, individual data points shown as dots, bars show mean ± SEM).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig6-v2.tif"/></fig></sec><sec id="s2-6"><title>Human cells lacking Skd3 exhibit reduced solubility of mitochondrial proteins</title><p>Given the potent disaggregase activity of Skd3, we predicted that deletion of Skd3 in human cells would result in decreased protein solubility in mitochondria. To determine the effect of Skd3 on protein solubility in mitochondria, we compared the relative solubility of the mitochondrial proteome in wild-type and Skd3 knockout human HAP1 cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a–c</xref>) using mass spectrometry as described in <xref ref-type="fig" rid="fig7">Figure 7a</xref>. Overall, we observed decreased protein solubility in mitochondria from the Skd3 knockout cells when compared to their wild-type counterparts (<xref ref-type="fig" rid="fig7">Figure 7b</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2a</xref>). Using Gene Ontology (GO) analysis for cellular component, we found that proteins in the inner mitochondrial membrane and intermembrane space were enriched in the insoluble fraction in the absence of Skd3 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2a</xref>; <xref ref-type="bibr" rid="bib3">Ashburner et al., 2000</xref>; <xref ref-type="bibr" rid="bib76">Mi et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">The Gene Ontology Consortium, 2019</xref>). Importantly, Skd3 has been localized to the mitochondrial intermembrane space (<xref ref-type="bibr" rid="bib7">Botham et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Hung et al., 2014</xref>; <xref ref-type="bibr" rid="bib139">Yoshinaka et al., 2019</xref>). Using GO analysis for biological process, we found that proteins involved in calcium import into mitochondria, chaperone-mediated protein transport, protein insertion into the mitochondrial inner membrane, mitochondrial electron transport, mitochondrial respiratory-chain complex assembly, and cellular response to hypoxia are more insoluble in Skd3 knockout cells compared to wild-type cells (<xref ref-type="fig" rid="fig7">Figure 7c</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2b</xref>; <xref ref-type="bibr" rid="bib3">Ashburner et al., 2000</xref>; <xref ref-type="bibr" rid="bib76">Mi et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">The Gene Ontology Consortium, 2019</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Skd3 maintains the solubility of key mitochondrial proteins in human cells.</title><p>(<bold>A</bold>) Schematic showing sedimentation assay design. HAP1 cells were lysed and the mitochondrial fraction was separated from the cytosolic fraction. The mitochondrial fraction was then lysed, and the soluble fraction was separated from the insoluble fraction via sedimentation. The samples were then either analyzed via mass-spectrometry or western blotting. (<bold>B</bold>) Volcano plot showing the log<sub>2</sub> fold change of protein in the Skd3 (<italic>CLPB</italic>) knockout pellet compared to the wild-type (WT) pellet. The 99 proteins that were enriched in the Skd3 pellet are highlighted in red. The 53 proteins that were enriched in the wild-type (WT) pellet are highlighted in green. Significance cutoffs were set as fold change &gt;2.0 and p&lt;0.05, indicated with blue dashed lines (N = 3, p&lt;0.05). (<bold>C</bold>) Select statistically significant terms for GO biological processes from the enriched proteins in the Skd3 knockout pellet. Dashed line shows p=0.05 (p&lt;0.05). For full list see <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2b</xref>. (<bold>D</bold>) Representative western blot of sedimentation assay showing relative solubility of HAX1 protein in wild-type (WT) and Skd3 (<italic>CLPB</italic>) knockout cells. Results show a marked decrease in HAX1 solubility when Skd3 is knocked out. (N = 3). (<bold>E</bold>) Quantification of HAX1 sedimentation assay shows an overall increase in the insoluble HAX1 relative to the total protein in the Skd3 (<italic>CLPB</italic>) knockout cell line. Quantification is normalized as signal in the pellet divided by the sum of the signal in the pellet and supernatant. The fraction in the pellet for the Skd3 knockout was compared to the wild-type cells using a two-way, unpaired, t-test. (N = 3, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Verification of Skd3 knockout and mitochondria isolation in HAP1 cells.</title><p>(<bold>A</bold>) Representative western blot of HAP1 cells showing knockout of Skd3. First and second lane show 100 ng load of recombinant <sub>MPP</sub>Skd3 and <sub>PARL</sub>Skd3. Anti-Skd3 (Abcam CAT# ab235349) and anti-COXIV (Abcam CAT# ab14744) antibodies were used. (<bold>B</bold>) Representative western blot of HAP1 whole cell lysate and mitochondria extract showing enrichment of the mitochondrial protein COXIV and depletion of the cytoplasmic protein GAPDH from whole cell lysates to mitochondrial extract (N = 3). (<bold>C</bold>) Quantification of the western blots from (<bold>B</bold>) showing the relative enrichment of COXIV:GAPDH in the purified mitochondria.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Skd3 deletion increases insolubility of mitochondrial inner membrane and intermembrane space proteins.</title><p>(<bold>A</bold>) Terms for GO cellular component associated with the enriched proteins in the Skd3 knockout pellet. Dashed line shows p=0.05 (p&lt;0.05). (<bold>B</bold>) Full list of terms for GO biological processes associated with the enriched proteins in the Skd3 knockout pellet. Dashed line shows p=0.05 (p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig7-figsupp2-v2.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Skd3 maintains the solubility of MICU2 in human cells.</title><p>(<bold>A</bold>) Representative western blot of sedimentation assay showing relative solubility of MICU2 protein in wild-type and Skd3 (<italic>CLPB</italic>) knockout cells. Results show a decrease in MICU2 solubility when Skd3 is knocked out. (N = 3). (<bold>B</bold>) Quantification of MICU2 sedimentation assay shows an overall increase in the insoluble MICU2 relative to the total protein in the Skd3 (<italic>CLPB</italic>) knockout cell line. Quantification is normalized as signal in the pellet divided by the sum of the signal in the pellet and supernatant. The fraction in the pellet for the Skd3 knockout was compared to the wild-type cells using a two-way, unpaired, t-test. (N = 3, individual data points shown as dots, bars show mean ± SEM, *p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig7-figsupp3-v2.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>HAX1 is a highly disordered protein.</title><p>(<bold>A</bold>) Domain map of HAX1 with IUPRED disorder prediction score plotted underneath (<xref ref-type="bibr" rid="bib75">Mészáros et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Mészáros et al., 2009</xref>). IUPRED scores higher than 0.5 predict disorder. Analysis suggests that HAX1 is a highly disordered protein. Acidic domain labeled in green, BH1 and BH2 domains labeled in purple, HD1 and HD2 domains labeled in blue, PEST domain labeled in orange, and transmembrane domain (TMD) labeled in tan.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig7-figsupp4-v2.tif"/></fig></fig-group><p>Specifically, we find that HAX1, OPA1, PHB2, PARL, SMAC/DIABLO, and HTRA2 are more insoluble, which implicates a key role for Skd3 in regulating apoptotic and proteolytic pathways (<xref ref-type="bibr" rid="bib5">Baumann et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Chai et al., 2000</xref>; <xref ref-type="bibr" rid="bib13">Chao et al., 2008</xref>; <xref ref-type="bibr" rid="bib16">Cipolat et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Frezza et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Klein et al., 2007</xref>; <xref ref-type="bibr" rid="bib99">Saita et al., 2017</xref>; <xref ref-type="bibr" rid="bib139">Yoshinaka et al., 2019</xref>). Additionally, the regulators of the mitochondrial calcium uniporter (MCU), MICU1 and MICU2 along with several members of the SLC25 family (including the calcium binding SLC25A25 and SLC25A13) were found to be more insoluble in the knockout compared to the wild type, implicating Skd3 in the regulation of mitochondrial calcium transport and signaling (<xref ref-type="bibr" rid="bib2">Anunciado-Koza et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Csordás et al., 2013</xref>; <xref ref-type="bibr" rid="bib85">Palmieri et al., 2001</xref>; <xref ref-type="bibr" rid="bib88">Patron et al., 2014</xref>; <xref ref-type="bibr" rid="bib90">Perocchi et al., 2010</xref>; <xref ref-type="bibr" rid="bib92">Plovanich et al., 2013</xref>). Indeed, a sedimentation assay as described in <xref ref-type="fig" rid="fig7">Figure 7a</xref> in combination with western blot analysis shows an overall decrease in solubility of MICU2 in mitochondria lacking Skd3 (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3a,b</xref>). We also observed an enrichment of translocase of the inner membrane (TIM) components, TIMM8A, TIMM8B, TIMM13, TIMM21, TIMM22, TIMM23, and TIMM50 in the insoluble fraction of Skd3 knockouts (<xref ref-type="bibr" rid="bib11">Chacinska et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Donzeau et al., 2000</xref>; <xref ref-type="bibr" rid="bib36">Geissler et al., 2002</xref>; <xref ref-type="bibr" rid="bib73">Meinecke et al., 2006</xref>; <xref ref-type="bibr" rid="bib80">Mokranjac et al., 2003</xref>; <xref ref-type="bibr" rid="bib87">Paschen et al., 2000</xref>; <xref ref-type="bibr" rid="bib114">Sirrenberg et al., 1996</xref>; <xref ref-type="bibr" rid="bib136">Yamamoto et al., 2002</xref>). Finally, we observed an enrichment in respiratory complex I and III proteins and their assembly factors such as NDUFA8, NDUFA11, NDUFA13, NDUFB7, NDUFB10, TTC19, COX11, and CYC1 in the insoluble fraction of Skd3 knockouts (<xref ref-type="fig" rid="fig6">Figure 6b</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>; <xref ref-type="bibr" rid="bib1">Angebault et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Ghezzi et al., 2011</xref>; <xref ref-type="bibr" rid="bib117">Spinazzi et al., 2019</xref>; <xref ref-type="bibr" rid="bib120">Szklarczyk et al., 2011</xref>; <xref ref-type="bibr" rid="bib127">Tzagoloff et al., 1990</xref>). Overall, these results suggest an important role for Skd3 in maintaining the solubility of proteins of the inner mitochondrial membrane and intermembrane space, including key regulators in apoptosis, mitochondrial calcium regulation, protein import, and respiration. Thus, in cells Skd3 appears critical for protein solubility in the intermembrane space and mitochondrial inner membrane.</p></sec><sec id="s2-7"><title>Skd3 promotes HAX1 solubility in human cells</title><p>HAX1 is a highly-disordered protein that has been previously identified as a Skd3 substrate both in cells and in silico (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>). HAX1 is an anti-apoptotic BCL-2 family protein that enables efficient cleavage of HTRA2 by PARL to promote cell survival (<xref ref-type="bibr" rid="bib13">Chao et al., 2008</xref>; <xref ref-type="bibr" rid="bib57">Klein et al., 2007</xref>). To test if Skd3 regulates HAX1 solubility in human cells, we compared the solubility of HAX1 in wild-type and Skd3-knockout HAP1 cells via sedimentation analysis and western blot. In wild-type cells, HAX1 remained predominantly soluble (<xref ref-type="fig" rid="fig7">Figure 7d,e</xref>). However, when Skd3 was deleted HAX1 became predominantly insoluble (<xref ref-type="fig" rid="fig7">Figure 7d,e</xref>). Thus, Skd3 is essential for HAX1 solubility in cells. Curiously, loss of Skd3 has been previously shown to promote apoptosis in specific contexts (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). Furthermore, HAX1 stability has been implicated as a regulator of apoptotic signaling (<xref ref-type="bibr" rid="bib5">Baumann et al., 2014</xref>). Our data support a model whereby Skd3 exerts its anti-apoptotic effect by maintaining HAX1 solubility and contingent functionality.</p></sec><sec id="s2-8"><title>MGCA7-linked Skd3 variants display diminished disaggregase activity</title><p>Skd3 has been implicated in a severe mitochondrial disorder, MGCA7, yet little is known about its contribution or function in this disease (<xref ref-type="bibr" rid="bib9">Capo-Chichi et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Kanabus et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Kiykim et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>; <xref ref-type="bibr" rid="bib101">Saunders et al., 2015</xref>; <xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>). Indeed, many mutations in Skd3 are connected with MGCA7 (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). Most of these are clustered in the NBD, but several are also in the ankyrin-repeat domain, and one frameshift is found in the mitochondrial targeting signal (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). Some MGCA7-linked Skd3 variants, such as R250* and K321* (where * indicates a stop codon), lack the NBD and would be predicted in light of our findings to be incapable protein disaggregation and indeed any ATPase-dependent activities (<xref ref-type="fig" rid="fig5">Figure 5b,c</xref>). We hypothesized that MGCA7-linked missense mutations also directly affect Skd3 disaggregase activity. To test this hypothesis, we purified MGCA7-linked variants of Skd3 from cases where both patient alleles bear the mutation, specifically: T268M, R475Q, A591V, and R650P (<xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>). These Skd3 variants cause MGCA7 on a spectrum of clinical severity, which is defined by a scoring system assigned by physicians based on the presentation of various symptoms associated with MGCA7 (<xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>). Broadly, the severe phenotype often presented with the absence of voluntary movements in neonates, hyperexcitability, ventilator dependency, and early death (<xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>). The ankyrin-repeat variant, T268M, is linked to moderate MGCA7, whereas the NBD variants (R475Q, A591V, and R650P) are linked to severe MGCA7 (<xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Skd3 disaggregase activity predicts the clinical severity of MGCA7-associated mutations.</title><p>(<bold>A</bold>) Domain map depicting all published mutations in Skd3 that have been associated with MGCA7. Mutants in red are studied further here. (<bold>B</bold>) ATPase assay showing the effect of four homozygous MGCA7 mutations on Skd3 activity. <sub>PARL</sub>Skd3<sup>T268M</sup> has increased ATPase activity, <sub>PARL</sub>Skd3<sup>R475Q</sup> and <sub>PARL</sub>Skd3<sup>A591V</sup> have decreased ATPase activity, and <sub>PARL</sub>Skd3<sup>R650P</sup> has unchanged ATPase activity compared to wild type. <sub>PARL</sub>Skd3 MGCA7 mutants ATPase activities were compared to <sub>PARL</sub>Skd3 wild-type using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>C</bold>) Luciferase disaggregation/reactivation assay showing the effect of the same four homozygous MGCA7 mutations on Skd3 activity. <sub>PARL</sub>Skd3<sup>T268M</sup> had reduced disaggregase activity, whereas <sub>PARL</sub>Skd3<sup>R475Q</sup>, <sub>PARL</sub>Skd3<sup>A591V</sup>, and <sub>PARL</sub>Skd3<sup>R650P</sup>were almost completely inactive compared to wild type. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Luciferase disaggregase activity was compared to <sub>PARL</sub>Skd3 wild type using one-way ANOVA and a Dunnett’s multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, ****p&lt;0.0001). (<bold>D</bold>) Table summarizing the clinical severity of each MGCA7 mutation as well as the ATPase activity and luciferase disaggregase activity. The table shows a relationship between luciferase disaggregase activity and clinical severity, but no relationship between either the ATPase activity and clinical severity or ATPase and luciferase disaggregase activity. Values represent ATPase activity and luciferase disaggregase activity normalized to wild-type <sub>PARL</sub>Skd3 activity. Values show mean ± SEM (N = 3).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig8-v2.tif"/></fig><p>Surprisingly, the ATPase activity varied for each MGCA7-linked variant. T268M had significantly increased ATPase activity, R475Q and A591V had marked decreased ATPase activity, and R650P ATPase was indistinguishable from wild type (<xref ref-type="fig" rid="fig8">Figure 8b</xref>). These ATPase activities did not correlate with clinical severity (<xref ref-type="fig" rid="fig8">Figure 8d</xref>; <xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>). Thus, Skd3 variant ATPase activity does not accurately predict MGCA7 severity, as the mutation associated with mild MGCA7 had elevated ATPase relative to wild type, whereas different mutations capable of causing severe MGCA7 could exhibit impaired or nearly wild-type ATPase activity.</p><p>To address the disconnect between ATPase activity and MGCA7 disease severity, we next tested the disaggregase activity of these MGCA7-linked variants. Strikingly, and in contrast to ATPase activity, we found disaggregase activity tracks closely with disease severity. T268M, the only moderate phenotype variant tested, had ~27% disaggregase activity compared to wild type. By contrast, the three severe MGCA7 variants, R475Q, A591V, and R650P abolish or diminish disaggregation activity with 0%, 0%, and ~4% disaggregation activity compared to wild type, respectively (<xref ref-type="fig" rid="fig8">Figure 8c</xref>). Thus, disaggregase activity but not ATPase activity, is tightly correlated with clinical severity of MGCA7-linked mutations (<xref ref-type="fig" rid="fig8">Figure 8d</xref>; <xref ref-type="bibr" rid="bib94">Pronicka et al., 2017</xref>). It will be of interest to test further MGCA7-linked variants to determine whether this trend holds. Nevertheless, our findings suggest that defects in Skd3 protein-disaggregase activity (and not other ATPase-related functions) are the driving factor in MGCA7 and pivotal to human health.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>At the evolutionary transition from protozoa to metazoa, the potent mitochondrial AAA+ protein disaggregase, Hsp78, was lost (<xref ref-type="bibr" rid="bib30">Erives and Fassler, 2015</xref>). Thus, it has long remained unknown whether metazoan mitochondria disaggregate and reactivate aggregated proteins. Here, we establish that another AAA+ protein, Skd3, is a potent metazoan mitochondrial protein disaggregase. Skd3 is activated by a mitochondrial inner-membrane rhomboid protease, PARL (<xref ref-type="fig" rid="fig9">Figure 9</xref>). PARL removes a hydrophobic auto-inhibitory sequence from the N-terminal region of Skd3, which prior to cleavage may limit Skd3 interactions with substrate (<xref ref-type="fig" rid="fig9">Figure 9</xref>). In this way, Skd3 only becomes fully activated as a disaggregase once it reaches its final cellular destination. Thus, cells might avoid any potential problems that could arise from unchecked Skd3 activity in the wrong cellular location. Skd3 activation by PARL may underlie several potential physiological mechanisms whereby Skd3 is either activated by PARL in response to certain cellular stressors or Skd3 is no longer activated by PARL upon the onset of apoptotic signaling.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Skd3 is a protein disaggregase that is activated by PARL and inactivated by MGCA7-linked mutations.</title><p>(<bold>A</bold>) Schematic illustrating (<bold>i</bold>) that Skd3 is a protein disaggregase that is activated by PARL cleavage of a hydrophobic auto-inhibitory peptide, (ii) that Skd3 works to solubilize key substrates in the mitochondrial intermembrane space and inner membrane that are involved in apoptosis, protein import, calcium handling, and respiration, and (iii) that mutations in Skd3 associated with MGCA7 result in defective Skd3 disaggregase activity in a manner that predicts the clinical severity of disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55279-fig9-v2.tif"/></fig><p>Skd3 couples ATP binding and hydrolysis to protein disaggregation. To do so, Skd3 utilizes conserved AAA+ motifs in its NBD, including the Walker A and B motifs to bind and hydrolyze ATP, as well as a conserved pore-loop tyrosine, which likely engages substrate directly in a manner similar to other HCLR clade AAA+ proteins (<xref ref-type="bibr" rid="bib31">Erzberger and Berger, 2006</xref>; <xref ref-type="bibr" rid="bib35">Gates et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Lopez et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Martin et al., 2008</xref>; <xref ref-type="bibr" rid="bib97">Rizo et al., 2019</xref>; <xref ref-type="bibr" rid="bib107">Seraphim and Houry, 2020</xref>). However, the isolated NBD is insufficient for disaggregase activity, which indicates an important role for the ankyrin-repeat domain. Intriguingly, an ankyrin-repeat domain is also important for the activity of an unrelated ATP-independent protein disaggregase, cpSRP43, where it makes critical contacts with substrate (<xref ref-type="bibr" rid="bib54">Jaru-Ampornpan et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Jaru-Ampornpan et al., 2010</xref>; <xref ref-type="bibr" rid="bib72">McAvoy et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Nguyen et al., 2013</xref>). Thus, ankyrin-repeat domains appear to be a recurring feature of diverse protein disaggregases.</p><p>Importantly, Skd3 is a stand-alone disaggregase and does not require Hsp70 and Hsp40 for maximal activity. This finding is consistent with the absence of Hsp70-interacting domains (NTD, NBD1, and MD) found in Hsp104, which enable collaboration with Hsp70 (<xref ref-type="bibr" rid="bib25">DeSantis et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Lee et al., 2013</xref>; <xref ref-type="bibr" rid="bib118">Sweeny et al., 2015</xref>; <xref ref-type="bibr" rid="bib119">Sweeny et al., 2020</xref>). Future structural and biochemical studies will further inform our mechanistic understanding of Skd3 disaggregase activity.</p><p>We establish that Skd3 can disaggregate disease-causing α-synuclein fibrils in vitro, demonstrating its robust activity as a disaggregase and identifying it as a potential therapeutic for synucleinopathies. The realization that human cells harbor a AAA+ protein disaggregase of greater potency than Hsp104 opens several therapeutic opportunities. Indeed, Skd3 is expressed in neurons and shifting localization of activated Skd3 to the cytoplasm could help combat cytoplasmic aggregates. Likewise, the expression of the <sub>PARL</sub>Skd3 enhanced variant in the cytoplasm of dopaminergic neurons may elicit therapeutic benefit similar to Hsp104 and engineered variants in Parkinson’s disease models (<xref ref-type="bibr" rid="bib50">Jackrel et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Lo Bianco et al., 2008</xref>; <xref ref-type="bibr" rid="bib67">Mack et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">March et al., 2020</xref>; <xref ref-type="bibr" rid="bib122">Tariq et al., 2019</xref>). Future studies will further inform our understanding of how to harness Skd3 disaggregase activity therapeutically in synucleinopathies such as Parkinson’s disease and other neurodegenerative diseases connected with aberrant protein aggregation.</p><p>We demonstrate that Skd3 is essential for maintaining the solubility of mitochondrial inner-membrane and intermembrane space protein complexes and specifically maintains solubility of the anti-apoptotic protein HAX1 in human cells (<xref ref-type="fig" rid="fig9">Figure 9</xref>). We suggest that HAX1 solubility is important for its anti-apoptotic effect. The precise mechanism of regulation between Skd3 and HAX1, PARL, OPA1, HTRA2, and SMAC/DIABLO warrants future study (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><p>In addition to finding that many human mitochondrial proteins are more insoluble in the absence of Skd3, a small fraction of proteins are more insoluble in the presence of Skd3. Closer analysis of these enriched proteins suggests that many are mitochondrial matrix-associated, especially mitoribosome proteins (<xref ref-type="fig" rid="fig7">Figure 7b</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The mitoribosome is a large, megadalton sized protein complex that is much more proteinaceous than its cytoplasmic counterpart and assembles into larger polysomes during active translation (<xref ref-type="bibr" rid="bib18">Couvillion et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Greber and Ban, 2016</xref>; <xref ref-type="bibr" rid="bib102">Saurer et al., 2019</xref>). Thus, changes in solubility of the mitoribosome components could be due to increased mitoribosome or polysome assembly in the presence of Skd3.</p><p>It is surprising that Skd3 maintains protein solubility in the mitochondrial intermembrane space and inner membrane, as Hsp78 is found in the mitochondrial matrix (<xref ref-type="bibr" rid="bib4">Bateman et al., 2002</xref>; <xref ref-type="bibr" rid="bib37">Germaniuk et al., 2002</xref>; <xref ref-type="bibr" rid="bib78">Moczko et al., 1995</xref>; <xref ref-type="bibr" rid="bib98">Rottgers et al., 2002</xref>; <xref ref-type="bibr" rid="bib103">Schmitt et al., 1995</xref>; <xref ref-type="bibr" rid="bib129">von Janowsky et al., 2006</xref>). Since Skd3 appears in evolution alongside Hsp78 in choanoflagellates it may have initially arisen to serve a distinct function. We hypothesize that the increasing number and complexity of mitochondrial inner membrane protein assemblies (such as MICU1/MICU2/MCU and respiratory complex I) in metazoa might necessitate the requirement of Skd3 activity in the inner mitochondrial membrane and intermembrane space to maintain proteostasis in these compartments (<xref ref-type="bibr" rid="bib7">Botham et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Hung et al., 2014</xref>; <xref ref-type="bibr" rid="bib139">Yoshinaka et al., 2019</xref>).</p><p>Hsp78 is known to be involved in mitochondrial protein import in yeast (<xref ref-type="bibr" rid="bib78">Moczko et al., 1995</xref>; <xref ref-type="bibr" rid="bib103">Schmitt et al., 1995</xref>). Furthermore, the ankyrin-repeat containing chloroplast disaggregase, cpSRP43, is involved in sorting membrane-targeted cargo (<xref ref-type="bibr" rid="bib54">Jaru-Ampornpan et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Jaru-Ampornpan et al., 2010</xref>). It is unknown if Skd3 participates in protein import and sorting in mitochondria. However, given the involvement of two closely related organelle-specific disaggregases in protein import and sorting and the changes in solubility of key TIM components in the absence of Skd3, it is plausible that Skd3 might play a role in protein import and sorting in mitochondria (<xref ref-type="fig" rid="fig7">Figure 7b,c</xref>). Mitochondrial presequences are prone to aggregation and the accumulation of uncleaved precursor aggregates can lead to the activation of an early mitochondrial unfolded protein response (mtUPR) (<xref ref-type="bibr" rid="bib29">Endo et al., 1995</xref>; <xref ref-type="bibr" rid="bib93">Poveda-Huertes et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yano et al., 2003</xref>). Skd3 might be required to keep aggregation-prone presequence signals in an unfolded state during import and sorting prior to cleavage or may help disaggregate them if they aggregate. Further investigation is required to determine which changes in protein solubility are driven by defects in Skd3 activity and which are from potential defects in mitochondrial protein import or membrane insertion.</p><p>Mutations in Skd3 are connected to MGCA7, which can be a devastating disorder involving severe neurologic deterioration, neutropenia, and death in infants (<xref ref-type="bibr" rid="bib135">Wortmann et al., 2016</xref>). Importantly, we establish that diverse MGCA7-linked mutations in Skd3 impair disaggregase activity, but not necessarily ATPase activity (<xref ref-type="fig" rid="fig9">Figure 9</xref>). The degree of impaired disaggregase activity predicts the clinical severity of the disease, which suggests that disaggregase activity is a critical factor in disease. However, it is yet unclear which Skd3 substrate or substrates contribute to the MGCA7 etiology. Our mass-spectrometry data suggest that MGCA7 arises due to severely compromised proteostasis in the mitochondrial inner-membrane and intermembrane space (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Hence, small-molecule drugs that restore wild-type levels of disaggregase activity to MGCA7-linked Skd3 variants could be valuable therapeutics.</p><p>Finally, Skd3 has also emerged as a factor in Venetoclax resistance, a FDA-approved drug for the treatment of acute myeloid leukemia (AML), which exerts its mechanism via BCL-2 inhibition (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). These studies suggest that inhibition of Skd3 may be of critical therapeutic importance for treating Venetoclax-resistant cancers (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). Small-molecule screens targeted at finding inhibitors of Skd3 disaggregase activity may yield important drugs for Venetoclax-resistant AML patients. Thus, the Skd3 disaggregase assays established in this study could provide a powerful platform for isolating therapeutic compounds for MGCA7 and AML.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Multiple sequence alignments</title><p>NBD sequences were acquired via UniProtKB for <italic>Homo sapiens</italic> Skd3, <italic>Saccharomyces cerevisiae</italic> Hsp104, <italic>Saccharomyces cerevisiae</italic> Hsp78, <italic>Escherichia coli</italic> ClpB, <italic>Escherichia coli</italic> ClpA, and <italic>Staphylococcus aureus</italic> ClpC. Skd3 sequences were acquired via SMART protein domain annotation resource (<xref ref-type="bibr" rid="bib61">Letunic and Bork, 2018</xref>). Sequences from <italic>Anolis carolinensis</italic>, <italic>Bos taurus</italic>, <italic>Callithrix jacchus</italic>, <italic>Canis lupus</italic>, <italic>Capra hircus</italic>, <italic>Danio rerio</italic>, <italic>Equus caballus</italic>, <italic>Geospiza fortis</italic>, <italic>Gorilla gorilla</italic>, <italic>Homo sapiens</italic>, <italic>Monosiga brevicollis</italic>, <italic>Mus musculus</italic>, <italic>Nothobranchius rachovii</italic>, <italic>Rattus norvegicus</italic>, <italic>Sus scrofa</italic>, <italic>Trachymyrmex septentrionalis</italic>, <italic>Trichinella papuae</italic>, and <italic>Xenopus laevis</italic> were used to generate alignment for <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Compiled sequences were aligned and made into a guide tree via Clustal Omega (<xref ref-type="bibr" rid="bib68">Madeira et al., 2019</xref>). Alignment image was generated via BoxShade tool (<xref ref-type="bibr" rid="bib48">Hofmann and Baron, 1996</xref>). Guide tree image was built using FigTree (<xref ref-type="bibr" rid="bib96">Rambaut, 2012</xref>). Species images were used under license via PhyloPic. Sequence logo was created using WebLogo and 42 mammalian Skd3 protein sequences (<italic>Ailuropoda melanoleuca</italic>, <italic>Callorhinus ursinus</italic>, <italic>Canis lupus</italic>, <italic>Carlito syrichta</italic>, <italic>Cebus capucinus</italic>, <italic>Ceratotherium simum</italic>, <italic>Cercocebus atys</italic>, <italic>Chlorocebus sabaeus</italic>, <italic>Colobus angolensis</italic>, <italic>Equus asinus, Equus caballus</italic>, <italic>Equus przewalskii</italic>, <italic>Felis catus</italic>, <italic>Gorilla gorilla</italic>, <italic>Gulo gulo</italic>, <italic>Grammomys surdaster</italic>, <italic>Homo sapiens</italic>, <italic>Macaca fascicularis</italic>, <italic>Macaca mulatta</italic>, <italic>Macaca nemestrina</italic>, <italic>Mandrillus leucophaeus</italic>, <italic>Microcebus murinus</italic>, <italic>Microtus ochrogaster</italic>, <italic>Mustela putorius</italic>, <italic>Nomascus leucogenys</italic>, <italic>Odobenus rosmarus</italic>, <italic>Orycteropus afer</italic>, <italic>Pan paniscus</italic>, <italic>Pan troglodyte</italic>, <italic>Panthera tigris</italic>, <italic>Papio anubis</italic>, <italic>Piliocolobus tephrosceles</italic>, <italic>Pongo abelii</italic>, <italic>Propithecus coquereli</italic>, <italic>Puma concolor</italic>, <italic>Rhinopithecus bieti</italic>, <italic>Rhinopithecus roxellana</italic>, <italic>Rousettus aegyptiacus</italic>, <italic>Theropithecus gelada</italic>, <italic>Ursus arctos</italic>, <italic>Ursus maritimus</italic>, and <italic>Zalophus californianus</italic>) (<xref ref-type="bibr" rid="bib20">Crooks et al., 2004</xref>; <xref ref-type="bibr" rid="bib105">Schneider and Stephens, 1990</xref>).</p></sec><sec id="s4-2"><title>Cloning MBP-Skd3 plasmids</title><p><sub>MPP</sub>Skd3, <sub>PARL</sub>Skd3, <sub>ANK</sub>Skd3, and <sub>NBD2</sub>Skd3 were cloned into the pMAL C2 plasmid with TEV site (<xref ref-type="bibr" rid="bib140">Yoshizawa et al., 2018</xref>) using Gibson assembly (<xref ref-type="bibr" rid="bib39">Gibson et al., 2009</xref>). The mitochondrial targeting signal was identified using MitoProt in agreement with previous work (<xref ref-type="bibr" rid="bib17">Claros and Vincens, 1996</xref>; <xref ref-type="bibr" rid="bib134">Wortmann et al., 2015</xref>). Site-directed mutagenesis was performed using QuikChange site-directed mutagenesis (Agilent) and confirmed by DNA sequencing.</p></sec><sec id="s4-3"><title>Purification of Skd3</title><p>Skd3 variants were expressed as an N-terminally MBP-tagged protein in BL21 (DE3) RIL cells (Agilent). Cells were lysed via sonication in 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% (w/v) glycerol, 5 mM ATP, 10 mM MgCl<sub>2</sub>, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail (one tablet/250 mL, Millipore Sigma). Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was applied to amylose resin (NEB). The column was washed with 15 column volumes (CV) of wash buffer (WB: 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% (w/v) glycerol, 5 mM ATP, 10 mM MgCl<sub>2</sub>, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail) at 4°C, 3 CV of WB supplemented with 20 mM ATP at 25°C for 30 min, and 15 CV of WB at 4°C. The protein was then exchanged into elution buffer (EB: 50 mM Tris-HCl pH = 8.0, 300 mM KCl, 10% glycerol, 5 mM ATP, 10 mM MgCl<sub>2</sub>, and 2 mM β-mercaptoethanol) with 8 CV and eluted via TEV cleavage at 34°C. The protein was then run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacryl S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 1 mM ATP, 10 mM MgCl<sub>2</sub>, and 1 mM DTT). Peak fractions were collected, concentrated to &gt;5 mg/mL, supplemented with 5 mM ATP, and snap frozen. Protein purity was determined to be &gt;95% by SDS-PAGE and Coomassie staining.</p></sec><sec id="s4-4"><title>Purification of Hsp104</title><p>Hsp104 was purified as previously described (<xref ref-type="bibr" rid="bib25">DeSantis et al., 2014</xref>). In brief, Hsp104 was expressed in BL21 (DE3) RIL cells, lysed via sonication in lysis buffer [50 mM Tris-HCl pH = 8.0, 10 mM MgCl<sub>2</sub>, 2.5% glycerol, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail (one mini EDTA-free tablet/50 mL, Millipore Sigma)], clarified via centrifugation at 30,597xg and 4°C for 20 min, and purified on Affi-Gel Blue Gel (Bio-Rad). Hsp104 was eluted in elution buffer (50 mM Tris-HCl pH = 8.0, 1M KCl, 10 mM MgCl<sub>2</sub>, 2.5% glycerol, and 2 mM β-mercaptoethanol) and then exchanged into storage buffer (40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20 mM MgCl<sub>2</sub>, 10% glycerol, 1 mM DTT). The protein was diluted to 10% in buffer Q (20 mM Tris-HCl pH = 8.0, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, and 0.5 mM EDTA) and loaded onto a 5 mL RESOURCE Q anion exchange chromatography (GE Healthcare). Hsp104 was eluted via linear gradient of buffer Q+ (20 mM Tris pH = 8.0, 1M NaCl, 5 mM MgCl<sub>2</sub>, and 0.5 mM EDTA). The protein was then exchanged into storage buffer and snap frozen. Protein purity was determined to be &gt;95% by SDS-PAGE and Coomassie staining.</p></sec><sec id="s4-5"><title>Purification of Hsc70 and Hdj1</title><p>Hsc70 and Hdj1 were purified as previously described (<xref ref-type="bibr" rid="bib77">Michalska et al., 2019</xref>). Hsc70 and Hdj1 were expressed in BL21 (DE3) RIL cells with an N-terminal His-SUMO tag. Cells were lysed via sonication into lysis buffer [50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 5 mM MgCl<sub>2</sub>, 10% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 5 µM pepstatin A, and cOmplete Protease Inhibitor Cocktail (one mini EDTA-free tablet/50 mL)]. Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was bound to Ni-NTA Agarose resin (Qiagen), washed with 10 CV of wash buffer (50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 10 mM MgCl<sub>2</sub>, 10% glycerol, 20 mM imidazole, 1 mM ATP, and 2 mM β-mercaptoethanol), and then eluted with 2 CV of elution buffer (wash buffer supplemented with 300 mM imidazole). The tag was removed via Ulp1 (1:100 Ulp1:Protein molar ratio) cleavage during dialysis into wash buffer. The protein was further purified via loading onto a 5 mL HisTrap HP column (GE Healthcare) and pooling the untagged elution. Cleaved protein was pooled, concentrated, purified further by Resource Q ion exchange chromatography, and snap frozen. Protein purity was determined to be &gt;95% by SDS-PAGE and Coomassie staining.</p></sec><sec id="s4-6"><title>ATPase assays</title><p>Proteins (0.25 µM monomer) were incubated with ATP (1 mM) (Innova Biosciences) at 37°C for 5 min (or otherwise indicated) in luciferase reactivation buffer (LRB; 25 mM HEPES-KOH [pH = 8.0], 150 mM KAOc, 10 mM MgAOc, 10 mM DTT). For substrate-stimulation of ATPase activity the indicated concentration of substrate was added. ATPase activity was assessed via inorganic phosphate release with a malachite green detection assay (Expedeon) and measured in Nunc 96 Well Optical plates on a Tecan Infinite M1000 plate reader. Background hydrolysis was measured at time zero and subtracted (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>).</p></sec><sec id="s4-7"><title>Luciferase disaggregation and reactivation assays</title><p>Firefly luciferase aggregates were formed by incubating luciferase (50 µM) in LRB (pH=7.4) plus 8M urea at 30°C for 30 min. The luciferase was then rapidly diluted 100-fold into LRB, snap frozen, and stored at −80°C until use. Hsp104 and Skd3 variants (1 µM monomer, unless otherwise indicated) were incubated with 50 nM aggregated firefly luciferase in the presence or absence of Hsc70 and Hdj2 (0.167 µM each) in LRB plus 5 mM ATP plus an ATP regeneration system (ARS; 1 mM creatine phosphate and 0.25 µM creatine kinase) at 37°C for 90 min (unless otherwise indicated). The nucleotide-dependence of Skd3 disaggregation activity was tested in the presence of ATP (Sigma), AMP-PNP (Roche), ATPγS (Roche), or ADP (MP Biomedicals) for 30 min at 37°C without ARS. Recovered luminescence was monitored in Nunc 96 Well Optical plates using a Tecan Infinite M1000 plate reader (<xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref>).</p></sec><sec id="s4-8"><title>α-Synuclein disaggregation assay</title><p>α-Synuclein fibrils were acquired from the Luk lab and formed as previously described (<xref ref-type="bibr" rid="bib64">Luk et al., 2012</xref>). <sub>PARL</sub>Skd3 (10 μM monomer) was incubated with α-synuclein fibrils (0.5 μM monomer) in LRB in the presence or absence of ARS (10 mM ATP, 10 mM creatine phosphate, 40 μg/mL creatine kinase) at 37°C for 90 min. The samples were then centrifuged at 4°C and 20,000xg for 20 min. After centrifugation the supernatants were pipetted off of the pellets and the pellets were boiled in Pellet Buffer (PB; 50 mM Tris-HCl [pH = 8.0], 8M Urea, 150 mM NaCl, 10 uL/1 mL mammalian PI cocktail [Sigma CAT# P8340]) for 5 min at 99°C. The total sample, supernatant, and pellet samples were then blotted on nitrocellulose membrane (ThermoFisher Scientific CAT# 88018) and incubated with the SYN211 antibody (ThermoFisher Scientific CAT# AHB0261). Blots were then incubated with the IRDye 800CW Goat anti-Mouse IgG Secondary Antibody (Li-COR CAT# 926–32210) and imaged using the Li-Cor Odyssey Fc Imaging System. Samples were quantified using FIJI and normalized as (signal in supernatant)/(signal in pellet + signal in supernatant).</p></sec><sec id="s4-9"><title>Western blots</title><p>Mammalian whole cell lysates were prepared by boiling 500,000 cells in 1x Sample Buffer (SB; 60 mM Tris-HCl [pH = 6.8], 5% glycerol, 2% SDS, 10% β-mercaptoethanol, 0.025% bromophenol blue, 1x Mammalian PI cocktail) for 5 min at 99°C. Sedimentation assay samples were prepared as described above. Western blot samples were boiled for 5 min at 99°C in 1x SB, separated by SDS-PAGE on a gradient gel (4%–20%, Bio-Rad CAT# 3450033), and transferred to a PVDF membrane. Membranes were blocked in Odyssey Blocking Buffer in PBS (Li-Cor CAT# 927–40000) for 1 hr at 25°C. Blots were then incubated in primary antibody overnight at 4°C and then in secondary for 30 min at 25°C. The antibodies used were: α-CLPB (Abcam CAT# ab235349), α-HAX1 (Abcam CAT# ab137613), α-COXIV (Abcam CAT# ab14744), α-GAPDH (Abcam CAT# ab8245), α-MICU2 (Abcam CAT# ab101465), IRDye 800CW Goat α-mouse secondary (Li-Cor CAT# 926–32210), and IRDye 680RD Goat α-rabbit secondary (Li-Cor CAT# 926–68071). Blots were imaged on a Li-Cor Odyssey Fc Imaging System.</p></sec><sec id="s4-10"><title>Mammalian cell culture</title><p>Isogenic HAP1 and HAP1 Δ<italic>CLPB</italic> cells were acquired directly from Horizon Discovery (CAT# HZGHC81570 and HZGHC007326c001) and have been control quality checked by the vendor. HAP1 cells are a human near-haploid cell line derived from the male chronic myelogenous leukemia (CML) cell line KBM-7 (<xref ref-type="bibr" rid="bib32">Essletzbichler et al., 2014</xref>). In brief, the <italic>CLPB</italic> knockout line was generated via CRISPR-Cas9 and the gRNA <named-content content-type="sequence">TGGCACGGGCAGCTTCCAAC</named-content> to make a 1 bp insertion into exon 2 of the <italic>CLPB</italic> gene. Knockout was confirmed by Sanger sequencing (DNA) by the vendor and western blot (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Cells were maintained in IMDM (Gibco CAT# 12440053) supplemented with 10% FBS (GE CAT# SH3007003) and 1% P/S (Gibco CAT# 15140122) at 37°C and 5% CO<sub>2</sub>. Cells were grown at a confluency of 50–60% for mitochondrial isolation.</p></sec><sec id="s4-11"><title>Mitochondrial isolation</title><p>Mitochondria were isolated as previously described (<xref ref-type="bibr" rid="bib34">Frezza et al., 2007</xref>). In brief, 50–100*10<sup>6</sup> cells were resuspended in 5 mL SM buffer (50 mM Tris-HCl [pH = 7.4], 0.25M sucrose, 2 mM EDTA, and 1% BSA) and homogenized with a Dounce homogenizer and Teflon pestle (30 strokes at 600 RPM) at 4°C. Lysate was then centrifuged at 600xg for 10 min. The supernatant was collected, and the pellet was dissolved in 5 mL SM buffer and homogenized (15 strokes at 600 RPM). Sample was then centrifuged at 600xg for 10 min and the supernatant was pooled and centrifuged at 12,000xg for 15 min. The pellet was collected and used for further experiments.</p></sec><sec id="s4-12"><title>Mitochondrial sedimentation assay</title><p>Mitochondrial sedimentation assay was performed essentially as previously described (<xref ref-type="bibr" rid="bib132">Wilkening et al., 2018</xref>). 60–80 μg isolated mitochondria were resuspended in 200 μL Mitochondrial Resuspension Buffer (40 mM HEPES-KOH, pH = 7.6, 500 mM sucrose, 120 mM K-acetate, 10 mM Mg-acetate, 5 mM glutamate, 5 mM malate, 5 mM EDTA, 5 mM ATP, 20 mM creatine phosphate, 4 μg/mL creatine kinase, 1 mM DTT) and incubated at 37°C for 20 min. The mitochondria were then pelleted at 12,000xg for 10 min at 4°C. The mitochondria were then resuspended in 200 μL Lysis Buffer (30 mM Tris-HCl, pH = 7.4, 200 mM KCl, 0.5% v/v Triton X-100, 5 mM EDTA, 0.5 mM PMSF, 1x Mammalian PI cocktail) and lysed in a thermomixer at 2,000 RPM for 10 min at 4°C. The protein concentration of the lysate was then quantified using a BCA assay (ThermoFisher CAT# 23225). 12 μg of lysate was added to a total volume of 50 μL Lysis Buffer and reserved as a total protein sample. 12 μg of lysate was added to a total volume of 50 μL Lysis Buffer and sedimented at 20,000xg for 20 min at 4°C. The supernatant was removed, TCA precipitated, and frozen for later processing. The pellet was boiled in 10 μL of Pellet Buffer and frozen for later processing.</p></sec><sec id="s4-13"><title>Mass spectrometry</title><p>Pellet samples were excised as whole lanes from gels, reduced with TCEP, alkylated with iodoacetamide, and digested with trypsin. Tryptic digests were desalted by loading onto a MonoCap C18 Trap Column (GL Sciences), flushed for 5 min at 6 μL/min using 100% Buffer A (H<sub>2</sub>0, 0.1% formic acid), then analyzed via LC (Waters NanoAcquity) gradient using Buffer A and Buffer B (acetonitrile, 0.1% formic acid) (initial 5% B; 75 min 30% B; 80 min 80% B; 90.5–105 min 5% B) on the Thermo Q Exactive HF mass spectrometer. Data were acquired in data-dependent mode. Analysis was performed with the following settings: MS1 60K resolution, AGC target 3e6, max inject time 50 ms; MS2 Top N = 20 15K resolution, AGC target 5e4, max inject time 50 ms, isolation window = 1.5 m/z, normalized collision energy 28%. LC-MS/MS data were searched with full tryptic specificity against the UniProt human database using MaxQuant 1.6.8.0. MS data were also searched for common protein N-terminal acetylation and methionine oxidation. Protein and peptide false discovery rate was set at 1%. LFQ intensity was calculated using the MaxLFQ algorithm (<xref ref-type="bibr" rid="bib19">Cox et al., 2014</xref>). Fold enrichment was calculated as LFQ intensity from the Δ<italic>CLPB</italic> pellet divided by the LFQ intensity from the wild-type pellet. High confidence hits were quantified as minimum absolute fold change of 2 and p-value&lt;0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Kelvin Luk, Douglas C Wallace, Prasanth Potluri, and Manisha Koneru for generously providing key reagents. We thank the Wistar Institute Proteomics and Metabolomics Facility for their assistance with the LC-MS/MS experiments, especially Hsin-Yao Tang and Thomas Beer. We thank Edward Barbieri, Edward Chuang, Kelvin Luk, Jordan Cupo, Albert Erives, Jan Fassler, Charlotte Fare, Oliver King, JiaBei Lin, Dylan Marchione, Zachary March, Hana Odeh, April Darling, and Bede Portz for feedback on the manuscript. Our work was funded by the Blavatnik Family Foundation Fellowship (RRC), The G Harold and Leila Y Mathers Foundation (JS), and NIH grants T32GM008275 (RRC), F31AG060672 (RRC), R01GM099836 (JS), and R21AG061784 (JS).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Alignment of Skd3 to diverse metazoan lineages shows conservation of key motifs and domains.</title><p>Alignment of Skd3 protein from diverse metazoan lineages. Alignment was constructed using Clustal Omega. Alignment shows high level of conservation of Skd3 among species. <italic>H. sapiens</italic>, <italic>G. gorilla</italic>, and <italic>C. jacchus</italic> Skd3 have an additional insertion in the ankyrin-repeat domain that is not conserved in the other species. This alignment was used to generate the phylogenetic tree in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. The protozoan <italic>M. brevicollis</italic> Skd3 sequence was included in the alignment for reference. MTS (mitochondrial-targeting sequence, ANK (ankyrin-repeat domain), NBD (nucleotide-binding domain), and CTD (C-terminal domain).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55279-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Proteins enriched in HAP1 <italic>ΔCLPB</italic> pellet.</title><p>Proteins from mass spectrometry data in <xref ref-type="fig" rid="fig7">Figure 7b</xref> highlighted in red that have &gt;2.0 fold change increase in the <italic>ΔCLPB</italic> insoluble fraction compared to wild type and a p-value of &lt;0.05.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55279-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Proteins enriched in HAP1 WT pellet.</title><p>Proteins from mass spectrometry data in <xref ref-type="fig" rid="fig7">Figure 7b</xref> highlighted in green that have &gt;2.0 fold change increase in the wild-type insoluble fraction compared to <italic>ΔCLPB</italic> and a p-value of &lt;0.05.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55279-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-55279-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angebault</surname> <given-names>C</given-names></name><name><surname>Charif</surname> <given-names>M</given-names></name><name><surname>Guegen</surname> <given-names>N</given-names></name><name><surname>Piro-Megy</surname> <given-names>C</given-names></name><name><surname>Mousson de Camaret</surname> <given-names>B</given-names></name><name><surname>Procaccio</surname> <given-names>V</given-names></name><name><surname>Guichet</surname> <given-names>PO</given-names></name><name><surname>Hebrard</surname> <given-names>M</given-names></name><name><surname>Manes</surname> <given-names>G</given-names></name><name><surname>Leboucq</surname> <given-names>N</given-names></name><name><surname>Rivier</surname> <given-names>F</given-names></name><name><surname>Hamel</surname> <given-names>CP</given-names></name><name><surname>Lenaers</surname> <given-names>G</given-names></name><name><surname>Roubertie</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation in NDUFA13/GRIM19 leads to early onset hypotonia, dyskinesia and sensorial deficiencies, and mitochondrial complex I instability</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>3948</fpage><lpage>3955</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv133</pub-id><pub-id pub-id-type="pmid">25901006</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anunciado-Koza</surname> <given-names>RP</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Ukropec</surname> <given-names>J</given-names></name><name><surname>Bajpeyi</surname> <given-names>S</given-names></name><name><surname>Koza</surname> <given-names>RA</given-names></name><name><surname>Rogers</surname> <given-names>RC</given-names></name><name><surname>Cefalu</surname> <given-names>WT</given-names></name><name><surname>Mynatt</surname> <given-names>RL</given-names></name><name><surname>Kozak</surname> <given-names>LP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inactivation of the mitochondrial carrier SLC25A25 (ATP-Mg2+/Pi transporter) reduces physical endurance and metabolic efficiency in mice</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>11659</fpage><lpage>11671</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.203000</pub-id><pub-id pub-id-type="pmid">21296886</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname> <given-names>M</given-names></name><name><surname>Ball</surname> <given-names>CA</given-names></name><name><surname>Blake</surname> <given-names>JA</given-names></name><name><surname>Botstein</surname> <given-names>D</given-names></name><name><surname>Butler</surname> <given-names>H</given-names></name><name><surname>Cherry</surname> <given-names>JM</given-names></name><name><surname>Davis</surname> <given-names>AP</given-names></name><name><surname>Dolinski</surname> <given-names>K</given-names></name><name><surname>Dwight</surname> <given-names>SS</given-names></name><name><surname>Eppig</surname> <given-names>JT</given-names></name><name><surname>Harris</surname> <given-names>MA</given-names></name><name><surname>Hill</surname> <given-names>DP</given-names></name><name><surname>Issel-Tarver</surname> <given-names>L</given-names></name><name><surname>Kasarskis</surname> <given-names>A</given-names></name><name><surname>Lewis</surname> <given-names>S</given-names></name><name><surname>Matese</surname> <given-names>JC</given-names></name><name><surname>Richardson</surname> <given-names>JE</given-names></name><name><surname>Ringwald</surname> <given-names>M</given-names></name><name><surname>Rubin</surname> <given-names>GM</given-names></name><name><surname>Sherlock</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Gene ontology: tool for the unification of biology the gene ontology consortium</article-title><source>Nature Genetics</source><volume>25</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname> <given-names>JM</given-names></name><name><surname>Iacovino</surname> <given-names>M</given-names></name><name><surname>Perlman</surname> <given-names>PS</given-names></name><name><surname>Butow</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mitochondrial DNA instability mutants of the bifunctional protein Ilv5p have altered organization in mitochondria and are targeted for degradation by Hsp78 and the Pim1p protease</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>47946</fpage><lpage>47953</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209071200</pub-id><pub-id pub-id-type="pmid">12381727</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname> <given-names>U</given-names></name><name><surname>Fernández-Sáiz</surname> <given-names>V</given-names></name><name><surname>Rudelius</surname> <given-names>M</given-names></name><name><surname>Lemeer</surname> <given-names>S</given-names></name><name><surname>Rad</surname> <given-names>R</given-names></name><name><surname>Knorn</surname> <given-names>AM</given-names></name><name><surname>Slawska</surname> <given-names>J</given-names></name><name><surname>Engel</surname> <given-names>K</given-names></name><name><surname>Jeremias</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Tomiatti</surname> <given-names>V</given-names></name><name><surname>Illert</surname> <given-names>AL</given-names></name><name><surname>Targosz</surname> <given-names>BS</given-names></name><name><surname>Braun</surname> <given-names>M</given-names></name><name><surname>Perner</surname> <given-names>S</given-names></name><name><surname>Leitges</surname> <given-names>M</given-names></name><name><surname>Klapper</surname> <given-names>W</given-names></name><name><surname>Dreyling</surname> <given-names>M</given-names></name><name><surname>Miething</surname> <given-names>C</given-names></name><name><surname>Lenz</surname> <given-names>G</given-names></name><name><surname>Rosenwald</surname> <given-names>A</given-names></name><name><surname>Peschel</surname> <given-names>C</given-names></name><name><surname>Keller</surname> <given-names>U</given-names></name><name><surname>Kuster</surname> <given-names>B</given-names></name><name><surname>Bassermann</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Disruption of the PRKCD-FBXO25-HAX-1 Axis attenuates the apoptotic response and drives lymphomagenesis</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1401</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/nm.3740</pub-id><pub-id pub-id-type="pmid">25419709</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beinker</surname> <given-names>P</given-names></name><name><surname>Schlee</surname> <given-names>S</given-names></name><name><surname>Auvula</surname> <given-names>R</given-names></name><name><surname>Reinstein</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Biochemical coupling of the two nucleotide binding domains of ClpB: covalent linkage is not a prerequisite for chaperone activity</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>37965</fpage><lpage>37973</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506672200</pub-id><pub-id pub-id-type="pmid">16162497</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botham</surname> <given-names>A</given-names></name><name><surname>Coyaud</surname> <given-names>E</given-names></name><name><surname>Nirmalanandhan</surname> <given-names>VS</given-names></name><name><surname>Gronda</surname> <given-names>M</given-names></name><name><surname>Hurren</surname> <given-names>R</given-names></name><name><surname>Maclean</surname> <given-names>N</given-names></name><name><surname>St‐Germain</surname> <given-names>J</given-names></name><name><surname>Mirali</surname> <given-names>S</given-names></name><name><surname>Laurent</surname> <given-names>E</given-names></name><name><surname>Raught</surname> <given-names>B</given-names></name><name><surname>Schimmer</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Global interactome mapping of mitochondrial intermembrane space proteases identifies a novel function for HTRA2</article-title><source>Proteomics</source><volume>19</volume><elocation-id>1900139</elocation-id><pub-id pub-id-type="doi">10.1002/pmic.201900139</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname> <given-names>T</given-names></name><name><surname>King</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The origin of animal multicellularity and cell differentiation</article-title><source>Developmental Cell</source><volume>43</volume><fpage>124</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.09.016</pub-id><pub-id pub-id-type="pmid">29065305</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capo-Chichi</surname> <given-names>JM</given-names></name><name><surname>Boissel</surname> <given-names>S</given-names></name><name><surname>Brustein</surname> <given-names>E</given-names></name><name><surname>Pickles</surname> <given-names>S</given-names></name><name><surname>Fallet-Bianco</surname> <given-names>C</given-names></name><name><surname>Nassif</surname> <given-names>C</given-names></name><name><surname>Patry</surname> <given-names>L</given-names></name><name><surname>Dobrzeniecka</surname> <given-names>S</given-names></name><name><surname>Liao</surname> <given-names>M</given-names></name><name><surname>Labuda</surname> <given-names>D</given-names></name><name><surname>Samuels</surname> <given-names>ME</given-names></name><name><surname>Hamdan</surname> <given-names>FF</given-names></name><name><surname>Vande Velde</surname> <given-names>C</given-names></name><name><surname>Rouleau</surname> <given-names>GA</given-names></name><name><surname>Drapeau</surname> <given-names>P</given-names></name><name><surname>Michaud</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disruption of <italic>CLPB</italic> is associated with congenital microcephaly, severe encephalopathy and 3-methylglutaconic aciduria</article-title><source>Journal of Medical Genetics</source><volume>52</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102952</pub-id><pub-id pub-id-type="pmid">25650066</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cashikar</surname> <given-names>AG</given-names></name><name><surname>Schirmer</surname> <given-names>EC</given-names></name><name><surname>Hattendorf</surname> <given-names>DA</given-names></name><name><surname>Glover</surname> <given-names>JR</given-names></name><name><surname>Ramakrishnan</surname> <given-names>MS</given-names></name><name><surname>Ware</surname> <given-names>DM</given-names></name><name><surname>Lindquist</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Defining a pathway of communication from the C-terminal peptide binding domain to the N-terminal ATPase domain in a AAA protein</article-title><source>Molecular Cell</source><volume>9</volume><fpage>751</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00499-9</pub-id><pub-id pub-id-type="pmid">11983167</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chacinska</surname> <given-names>A</given-names></name><name><surname>Lind</surname> <given-names>M</given-names></name><name><surname>Frazier</surname> <given-names>AE</given-names></name><name><surname>Dudek</surname> <given-names>J</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Geissler</surname> <given-names>A</given-names></name><name><surname>Sickmann</surname> <given-names>A</given-names></name><name><surname>Meyer</surname> <given-names>HE</given-names></name><name><surname>Truscott</surname> <given-names>KN</given-names></name><name><surname>Guiard</surname> <given-names>B</given-names></name><name><surname>Pfanner</surname> <given-names>N</given-names></name><name><surname>Rehling</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mitochondrial presequence translocase: switching between TOM tethering and motor recruitment involves Tim21 and Tim17</article-title><source>Cell</source><volume>120</volume><fpage>817</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.01.011</pub-id><pub-id pub-id-type="pmid">15797382</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname> <given-names>J</given-names></name><name><surname>Du</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>JW</given-names></name><name><surname>Kyin</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Structural and biochemical basis of apoptotic activation by smac/DIABLO</article-title><source>Nature</source><volume>406</volume><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1038/35022514</pub-id><pub-id pub-id-type="pmid">10972280</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname> <given-names>JR</given-names></name><name><surname>Parganas</surname> <given-names>E</given-names></name><name><surname>Boyd</surname> <given-names>K</given-names></name><name><surname>Hong</surname> <given-names>CY</given-names></name><name><surname>Opferman</surname> <given-names>JT</given-names></name><name><surname>Ihle</surname> <given-names>JN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hax1-mediated processing of HtrA2 by parl allows survival of lymphocytes and neurons</article-title><source>Nature</source><volume>452</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nature06604</pub-id><pub-id pub-id-type="pmid">18288109</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Glytsou</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Narang</surname> <given-names>S</given-names></name><name><surname>Reyna</surname> <given-names>DE</given-names></name><name><surname>Lopez</surname> <given-names>A</given-names></name><name><surname>Sakellaropoulos</surname> <given-names>T</given-names></name><name><surname>Gong</surname> <given-names>Y</given-names></name><name><surname>Kloetgen</surname> <given-names>A</given-names></name><name><surname>Yap</surname> <given-names>YS</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Gavathiotis</surname> <given-names>E</given-names></name><name><surname>Tsirigos</surname> <given-names>A</given-names></name><name><surname>Tibes</surname> <given-names>R</given-names></name><name><surname>Aifantis</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>890</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0117</pub-id><pub-id pub-id-type="pmid">31048321</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Hori</surname> <given-names>AM</given-names></name><name><surname>Hesketh</surname> <given-names>CD</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Amyloid assembly and disassembly</article-title><source>Journal of Cell Science</source><volume>131</volume><elocation-id>jcs189928</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.189928</pub-id><pub-id pub-id-type="pmid">29654159</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipolat</surname> <given-names>S</given-names></name><name><surname>Rudka</surname> <given-names>T</given-names></name><name><surname>Hartmann</surname> <given-names>D</given-names></name><name><surname>Costa</surname> <given-names>V</given-names></name><name><surname>Serneels</surname> <given-names>L</given-names></name><name><surname>Craessaerts</surname> <given-names>K</given-names></name><name><surname>Metzger</surname> <given-names>K</given-names></name><name><surname>Frezza</surname> <given-names>C</given-names></name><name><surname>Annaert</surname> <given-names>W</given-names></name><name><surname>D'Adamio</surname> <given-names>L</given-names></name><name><surname>Derks</surname> <given-names>C</given-names></name><name><surname>Dejaegere</surname> <given-names>T</given-names></name><name><surname>Pellegrini</surname> <given-names>L</given-names></name><name><surname>D'Hooge</surname> <given-names>R</given-names></name><name><surname>Scorrano</surname> <given-names>L</given-names></name><name><surname>De Strooper</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling</article-title><source>Cell</source><volume>126</volume><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.021</pub-id><pub-id pub-id-type="pmid">16839884</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claros</surname> <given-names>MG</given-names></name><name><surname>Vincens</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Computational method to predict mitochondrially imported proteins and their targeting sequences</article-title><source>European Journal of Biochemistry</source><volume>241</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1996.00779.x</pub-id><pub-id pub-id-type="pmid">8944766</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvillion</surname> <given-names>MT</given-names></name><name><surname>Soto</surname> <given-names>IC</given-names></name><name><surname>Shipkovenska</surname> <given-names>G</given-names></name><name><surname>Churchman</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Synchronized mitochondrial and cytosolic translation programs</article-title><source>Nature</source><volume>533</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/nature18015</pub-id><pub-id pub-id-type="pmid">27225121</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Hein</surname> <given-names>MY</given-names></name><name><surname>Luber</surname> <given-names>CA</given-names></name><name><surname>Paron</surname> <given-names>I</given-names></name><name><surname>Nagaraj</surname> <given-names>N</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2513</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id><pub-id pub-id-type="pmid">24942700</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crooks</surname> <given-names>GE</given-names></name><name><surname>Hon</surname> <given-names>G</given-names></name><name><surname>Chandonia</surname> <given-names>JM</given-names></name><name><surname>Brenner</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>WebLogo: a sequence logo generator</article-title><source>Genome Research</source><volume>14</volume><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1101/gr.849004</pub-id><pub-id pub-id-type="pmid">15173120</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csordás</surname> <given-names>G</given-names></name><name><surname>Golenár</surname> <given-names>T</given-names></name><name><surname>Seifert</surname> <given-names>EL</given-names></name><name><surname>Kamer</surname> <given-names>KJ</given-names></name><name><surname>Sancak</surname> <given-names>Y</given-names></name><name><surname>Perocchi</surname> <given-names>F</given-names></name><name><surname>Moffat</surname> <given-names>C</given-names></name><name><surname>Weaver</surname> <given-names>D</given-names></name><name><surname>de la Fuente Perez</surname> <given-names>S</given-names></name><name><surname>Bogorad</surname> <given-names>R</given-names></name><name><surname>Koteliansky</surname> <given-names>V</given-names></name><name><surname>Adijanto</surname> <given-names>J</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Hajnóczky</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca²⁺ uniporter</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>976</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.020</pub-id><pub-id pub-id-type="pmid">23747253</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cushman-Nick</surname> <given-names>M</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hsp104 suppresses polyglutamine-induced degeneration post onset in a <italic>Drosophila</italic> MJD/SCA3 model</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003781</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003781</pub-id><pub-id pub-id-type="pmid">24039611</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandoy-Dron</surname> <given-names>F</given-names></name><name><surname>Bogdanova</surname> <given-names>A</given-names></name><name><surname>Beringue</surname> <given-names>V</given-names></name><name><surname>Bailly</surname> <given-names>Y</given-names></name><name><surname>Tovey</surname> <given-names>MG</given-names></name><name><surname>Laude</surname> <given-names>H</given-names></name><name><surname>Dron</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons</article-title><source>Neuroscience Letters</source><volume>405</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2006.05.066</pub-id><pub-id pub-id-type="pmid">16884849</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname> <given-names>ME</given-names></name><name><surname>Leung</surname> <given-names>EH</given-names></name><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Cushman-Nick</surname> <given-names>M</given-names></name><name><surname>Neuhaus-Follini</surname> <given-names>A</given-names></name><name><surname>Vashist</surname> <given-names>S</given-names></name><name><surname>Sochor</surname> <given-names>MA</given-names></name><name><surname>Knight</surname> <given-names>MN</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients</article-title><source>Cell</source><volume>151</volume><fpage>778</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.09.038</pub-id><pub-id pub-id-type="pmid">23141537</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname> <given-names>ME</given-names></name><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Snead</surname> <given-names>D</given-names></name><name><surname>Leung</surname> <given-names>EH</given-names></name><name><surname>Go</surname> <given-names>MS</given-names></name><name><surname>Gupta</surname> <given-names>K</given-names></name><name><surname>Wendler</surname> <given-names>P</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation</article-title><source>Journal of Biological Chemistry</source><volume>289</volume><fpage>848</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.520759</pub-id><pub-id pub-id-type="pmid">24280225</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donzeau</surname> <given-names>M</given-names></name><name><surname>Káldi</surname> <given-names>K</given-names></name><name><surname>Adam</surname> <given-names>A</given-names></name><name><surname>Paschen</surname> <given-names>S</given-names></name><name><surname>Wanner</surname> <given-names>G</given-names></name><name><surname>Guiard</surname> <given-names>B</given-names></name><name><surname>Bauer</surname> <given-names>MF</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Brunner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Tim23 links the inner and outer mitochondrial membranes</article-title><source>Cell</source><volume>101</volume><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80850-8</pub-id><pub-id pub-id-type="pmid">10830167</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duennwald</surname> <given-names>ML</given-names></name><name><surname>Echeverria</surname> <given-names>A</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans</article-title><source>PLOS Biology</source><volume>10</volume><elocation-id>e1001346</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001346</pub-id><pub-id pub-id-type="pmid">22723742</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisele</surname> <given-names>YS</given-names></name><name><surname>Monteiro</surname> <given-names>C</given-names></name><name><surname>Fearns</surname> <given-names>C</given-names></name><name><surname>Encalada</surname> <given-names>SE</given-names></name><name><surname>Wiseman</surname> <given-names>RL</given-names></name><name><surname>Powers</surname> <given-names>ET</given-names></name><name><surname>Kelly</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting protein aggregation for the treatment of degenerative diseases</article-title><source>Nature Reviews Drug Discovery</source><volume>14</volume><fpage>759</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/nrd4593</pub-id><pub-id pub-id-type="pmid">26338154</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname> <given-names>T</given-names></name><name><surname>Mitsui</surname> <given-names>S</given-names></name><name><surname>Roise</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Mitochondrial presequences can induce aggregation of unfolded proteins</article-title><source>FEBS Letters</source><volume>359</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(95)00015-2</pub-id><pub-id pub-id-type="pmid">7851539</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erives</surname> <given-names>AJ</given-names></name><name><surname>Fassler</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0117192</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0117192</pub-id><pub-id pub-id-type="pmid">25710177</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erzberger</surname> <given-names>JP</given-names></name><name><surname>Berger</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Evolutionary relationships and structural mechanisms of AAA+ proteins</article-title><source>Annual Review of Biophysics and Biomolecular Structure</source><volume>35</volume><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.35.040405.101933</pub-id><pub-id pub-id-type="pmid">16689629</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essletzbichler</surname> <given-names>P</given-names></name><name><surname>Konopka</surname> <given-names>T</given-names></name><name><surname>Santoro</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Gapp</surname> <given-names>BV</given-names></name><name><surname>Kralovics</surname> <given-names>R</given-names></name><name><surname>Brummelkamp</surname> <given-names>TR</given-names></name><name><surname>Nijman</surname> <given-names>SM</given-names></name><name><surname>Bürckstümmer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line</article-title><source>Genome Research</source><volume>24</volume><fpage>2059</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1101/gr.177220.114</pub-id><pub-id pub-id-type="pmid">25373145</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname> <given-names>C</given-names></name><name><surname>Cipolat</surname> <given-names>S</given-names></name><name><surname>Martins de Brito</surname> <given-names>O</given-names></name><name><surname>Micaroni</surname> <given-names>M</given-names></name><name><surname>Beznoussenko</surname> <given-names>GV</given-names></name><name><surname>Rudka</surname> <given-names>T</given-names></name><name><surname>Bartoli</surname> <given-names>D</given-names></name><name><surname>Polishuck</surname> <given-names>RS</given-names></name><name><surname>Danial</surname> <given-names>NN</given-names></name><name><surname>De Strooper</surname> <given-names>B</given-names></name><name><surname>Scorrano</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion</article-title><source>Cell</source><volume>126</volume><fpage>177</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.025</pub-id><pub-id pub-id-type="pmid">16839885</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname> <given-names>C</given-names></name><name><surname>Cipolat</surname> <given-names>S</given-names></name><name><surname>Scorrano</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts</article-title><source>Nature Protocols</source><volume>2</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.478</pub-id><pub-id pub-id-type="pmid">17406588</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname> <given-names>SN</given-names></name><name><surname>Yokom</surname> <given-names>AL</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Rizo</surname> <given-names>AN</given-names></name><name><surname>Kendsersky</surname> <given-names>NM</given-names></name><name><surname>Buell</surname> <given-names>CE</given-names></name><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Mack</surname> <given-names>KL</given-names></name><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Torrente</surname> <given-names>MP</given-names></name><name><surname>Su</surname> <given-names>M</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104</article-title><source>Science</source><volume>357</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1126/science.aan1052</pub-id><pub-id pub-id-type="pmid">28619716</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissler</surname> <given-names>A</given-names></name><name><surname>Chacinska</surname> <given-names>A</given-names></name><name><surname>Truscott</surname> <given-names>KN</given-names></name><name><surname>Wiedemann</surname> <given-names>N</given-names></name><name><surname>Brandner</surname> <given-names>K</given-names></name><name><surname>Sickmann</surname> <given-names>A</given-names></name><name><surname>Meyer</surname> <given-names>HE</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Pfanner</surname> <given-names>N</given-names></name><name><surname>Rehling</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The mitochondrial presequence translocase: an essential role of Tim50 in directing preproteins to the import channel</article-title><source>Cell</source><volume>111</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)01073-5</pub-id><pub-id pub-id-type="pmid">12437924</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germaniuk</surname> <given-names>A</given-names></name><name><surname>Liberek</surname> <given-names>K</given-names></name><name><surname>Marszalek</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A bichaperone (Hsp70-Hsp78) system restores mitochondrial DNA synthesis following thermal inactivation of Mip1p polymerase</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>27801</fpage><lpage>27808</lpage><pub-id pub-id-type="doi">10.1074/jbc.M201756200</pub-id><pub-id pub-id-type="pmid">12023279</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname> <given-names>D</given-names></name><name><surname>Arzuffi</surname> <given-names>P</given-names></name><name><surname>Zordan</surname> <given-names>M</given-names></name><name><surname>Da Re</surname> <given-names>C</given-names></name><name><surname>Lamperti</surname> <given-names>C</given-names></name><name><surname>Benna</surname> <given-names>C</given-names></name><name><surname>D'Adamo</surname> <given-names>P</given-names></name><name><surname>Diodato</surname> <given-names>D</given-names></name><name><surname>Costa</surname> <given-names>R</given-names></name><name><surname>Mariotti</surname> <given-names>C</given-names></name><name><surname>Uziel</surname> <given-names>G</given-names></name><name><surname>Smiderle</surname> <given-names>C</given-names></name><name><surname>Zeviani</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies</article-title><source>Nature Genetics</source><volume>43</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/ng.761</pub-id><pub-id pub-id-type="pmid">21278747</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname> <given-names>DG</given-names></name><name><surname>Young</surname> <given-names>L</given-names></name><name><surname>Chuang</surname> <given-names>RY</given-names></name><name><surname>Venter</surname> <given-names>JC</given-names></name><name><surname>Hutchison</surname> <given-names>CA</given-names></name><name><surname>Smith</surname> <given-names>HO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title><source>Nature Methods</source><volume>6</volume><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1318</pub-id><pub-id pub-id-type="pmid">19363495</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname> <given-names>JR</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins</article-title><source>Cell</source><volume>94</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81223-4</pub-id><pub-id pub-id-type="pmid">9674429</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goloubinoff</surname> <given-names>P</given-names></name><name><surname>Mogk</surname> <given-names>A</given-names></name><name><surname>Zvi</surname> <given-names>AP</given-names></name><name><surname>Tomoyasu</surname> <given-names>T</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Sequential mechanism of solubilization and refolding of stable protein aggregates by a bichaperone network</article-title><source>PNAS</source><volume>96</volume><fpage>13732</fpage><lpage>13737</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.24.13732</pub-id><pub-id pub-id-type="pmid">10570141</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greber</surname> <given-names>BJ</given-names></name><name><surname>Ban</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure and function of the mitochondrial ribosome</article-title><source>Annual Review of Biochemistry</source><volume>85</volume><fpage>103</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014343</pub-id><pub-id pub-id-type="pmid">27023846</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Monaghan</surname> <given-names>J</given-names></name><name><surname>Freyermuth</surname> <given-names>F</given-names></name><name><surname>Sung</surname> <given-names>JC</given-names></name><name><surname>O’Donovan</surname> <given-names>K</given-names></name><name><surname>Fare</surname> <given-names>CM</given-names></name><name><surname>Diaz</surname> <given-names>Z</given-names></name><name><surname>Singh</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>ZC</given-names></name><name><surname>Coughlin</surname> <given-names>M</given-names></name><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>DeSantis</surname> <given-names>ME</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Rodell</surname> <given-names>CB</given-names></name><name><surname>Burdick</surname> <given-names>JA</given-names></name><name><surname>King</surname> <given-names>OD</given-names></name><name><surname>Gitler</surname> <given-names>AD</given-names></name><name><surname>Lagier-Tourenne</surname> <given-names>C</given-names></name><name><surname>Pandey</surname> <given-names>UB</given-names></name><name><surname>Chook</surname> <given-names>YM</given-names></name><name><surname>Taylor</surname> <given-names>JP</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nuclear-Import receptors reverse aberrant phase transitions of RNA-Binding proteins with Prion-like domains</article-title><source>Cell</source><volume>173</volume><fpage>677</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.002</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Fare</surname> <given-names>CM</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Therapeutic dissolution of aberrant phases by Nuclear-Import receptors</article-title><source>Trends in Cell Biology</source><volume>29</volume><fpage>308</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.12.004</pub-id><pub-id pub-id-type="pmid">30660504</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname> <given-names>PI</given-names></name><name><surname>Whiteheart</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>AAA+ proteins: have engine, will work</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>6</volume><fpage>519</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/nrm1684</pub-id><pub-id pub-id-type="pmid">16072036</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattendorf</surname> <given-names>DA</given-names></name><name><surname>Lindquist</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Analysis of the AAA sensor-2 motif in the C-terminal ATPase domain of Hsp104 with a site-specific fluorescent probe of nucleotide binding</article-title><source>PNAS</source><volume>99</volume><fpage>2732</fpage><lpage>2737</lpage><pub-id pub-id-type="doi">10.1073/pnas.261693199</pub-id><pub-id pub-id-type="pmid">11867765</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname> <given-names>MX</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>Lee</surname> <given-names>VM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies</article-title><source>Neuroscience Letters</source><volume>709</volume><elocation-id>134316</elocation-id><pub-id pub-id-type="doi">10.1016/j.neulet.2019.134316</pub-id><pub-id pub-id-type="pmid">31170426</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>K</given-names></name><name><surname>Baron</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="1996">1996</year><data-title>Boxshade is in the Pretty printing and shading of multiple-alignment files</data-title><source>Github</source><version designator="3.21">3.21</version><ext-link ext-link-type="uri" xlink:href="https://github.com/mdbaron42/pyBoxshade">https://github.com/mdbaron42/pyBoxshade</ext-link></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname> <given-names>V</given-names></name><name><surname>Zou</surname> <given-names>P</given-names></name><name><surname>Rhee</surname> <given-names>HW</given-names></name><name><surname>Udeshi</surname> <given-names>ND</given-names></name><name><surname>Cracan</surname> <given-names>V</given-names></name><name><surname>Svinkina</surname> <given-names>T</given-names></name><name><surname>Carr</surname> <given-names>SA</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Ting</surname> <given-names>AY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteomic mapping of the human mitochondrial intermembrane space in live cells via ratiometric APEX tagging</article-title><source>Molecular Cell</source><volume>55</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.06.003</pub-id><pub-id pub-id-type="pmid">25002142</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>DeSantis</surname> <given-names>ME</given-names></name><name><surname>Martinez</surname> <given-names>BA</given-names></name><name><surname>Castellano</surname> <given-names>LM</given-names></name><name><surname>Stewart</surname> <given-names>RM</given-names></name><name><surname>Caldwell</surname> <given-names>KA</given-names></name><name><surname>Caldwell</surname> <given-names>GA</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events</article-title><source>Cell</source><volume>156</volume><fpage>170</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.047</pub-id><pub-id pub-id-type="pmid">24439375</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Yee</surname> <given-names>K</given-names></name><name><surname>Tariq</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>AI</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disparate mutations confer therapeutic gain of Hsp104 function</article-title><source>ACS Chemical Biology</source><volume>10</volume><fpage>2672</fpage><lpage>2679</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00765</pub-id><pub-id pub-id-type="pmid">26441009</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins</article-title><source>Disease Models &amp; Mechanisms</source><volume>7</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1242/dmm.016113</pub-id><pub-id pub-id-type="pmid">25062688</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaru-Ampornpan</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>K</given-names></name><name><surname>Lam</surname> <given-names>VQ</given-names></name><name><surname>Ali</surname> <given-names>M</given-names></name><name><surname>Doniach</surname> <given-names>S</given-names></name><name><surname>Jia</surname> <given-names>TZ</given-names></name><name><surname>Shan</surname> <given-names>S-ou</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ATP-independent reversal of a membrane protein aggregate by a chloroplast SRP subunit</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>696</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1836</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaru-Ampornpan</surname> <given-names>P</given-names></name><name><surname>Liang</surname> <given-names>FC</given-names></name><name><surname>Nisthal</surname> <given-names>A</given-names></name><name><surname>Nguyen</surname> <given-names>TX</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>K</given-names></name><name><surname>Mayo</surname> <given-names>SL</given-names></name><name><surname>Shan</surname> <given-names>SO</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanism of an ATP-independent protein disaggregase: ii. distinct molecular interactions drive multiple steps during aggregate disassembly</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>13431</fpage><lpage>13445</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.462861</pub-id><pub-id pub-id-type="pmid">23519468</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanabus</surname> <given-names>M</given-names></name><name><surname>Shahni</surname> <given-names>R</given-names></name><name><surname>Saldanha</surname> <given-names>JW</given-names></name><name><surname>Murphy</surname> <given-names>E</given-names></name><name><surname>Plagnol</surname> <given-names>V</given-names></name><name><surname>Hoff</surname> <given-names>WV</given-names></name><name><surname>Heales</surname> <given-names>S</given-names></name><name><surname>Rahman</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bi-allelic CLPB mutations cause cataract, renal cysts, nephrocalcinosis and 3-methylglutaconic aciduria, a novel disorder of mitochondrial protein disaggregation</article-title><source>Journal of Inherited Metabolic Disease</source><volume>38</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1007/s10545-015-9813-0</pub-id><pub-id pub-id-type="pmid">25595726</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiykim</surname> <given-names>A</given-names></name><name><surname>Garncarz</surname> <given-names>W</given-names></name><name><surname>Karakoc-Aydiner</surname> <given-names>E</given-names></name><name><surname>Ozen</surname> <given-names>A</given-names></name><name><surname>Kiykim</surname> <given-names>E</given-names></name><name><surname>Yesil</surname> <given-names>G</given-names></name><name><surname>Boztug</surname> <given-names>K</given-names></name><name><surname>Baris</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel CLPB mutation in a patient with 3-methylglutaconic aciduria causing severe neurological involvement and congenital neutropenia</article-title><source>Clinical Immunology</source><volume>165</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2016.02.008</pub-id><pub-id pub-id-type="pmid">26916670</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>C</given-names></name><name><surname>Grudzien</surname> <given-names>M</given-names></name><name><surname>Appaswamy</surname> <given-names>G</given-names></name><name><surname>Germeshausen</surname> <given-names>M</given-names></name><name><surname>Sandrock</surname> <given-names>I</given-names></name><name><surname>Schäffer</surname> <given-names>AA</given-names></name><name><surname>Rathinam</surname> <given-names>C</given-names></name><name><surname>Boztug</surname> <given-names>K</given-names></name><name><surname>Schwinzer</surname> <given-names>B</given-names></name><name><surname>Rezaei</surname> <given-names>N</given-names></name><name><surname>Bohn</surname> <given-names>G</given-names></name><name><surname>Melin</surname> <given-names>M</given-names></name><name><surname>Carlsson</surname> <given-names>G</given-names></name><name><surname>Fadeel</surname> <given-names>B</given-names></name><name><surname>Dahl</surname> <given-names>N</given-names></name><name><surname>Palmblad</surname> <given-names>J</given-names></name><name><surname>Henter</surname> <given-names>JI</given-names></name><name><surname>Zeidler</surname> <given-names>C</given-names></name><name><surname>Grimbacher</surname> <given-names>B</given-names></name><name><surname>Welte</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)</article-title><source>Nature Genetics</source><volume>39</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/ng1940</pub-id><pub-id pub-id-type="pmid">17187068</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzewska</surname> <given-names>J</given-names></name><name><surname>Langer</surname> <given-names>T</given-names></name><name><surname>Liberek</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mitochondrial Hsp78, a member of the clp/Hsp100 family in <italic>Saccharomyces cerevisiae</italic>, cooperates with Hsp70 in protein refolding</article-title><source>FEBS Letters</source><volume>489</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)02423-6</pub-id><pub-id pub-id-type="pmid">11231020</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyte</surname> <given-names>J</given-names></name><name><surname>Doolittle</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>A simple method for displaying the hydropathic character of a protein</article-title><source>Journal of Molecular Biology</source><volume>157</volume><fpage>105</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(82)90515-0</pub-id><pub-id pub-id-type="pmid">7108955</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Biter</surname> <given-names>AB</given-names></name><name><surname>Sielaff</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Tsai</surname> <given-names>FT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Heat shock protein (Hsp) 70 is an activator of the Hsp104 motor</article-title><source>PNAS</source><volume>110</volume><fpage>8513</fpage><lpage>8518</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217988110</pub-id><pub-id pub-id-type="pmid">23650362</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letunic</surname> <given-names>I</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>20 years of the SMART protein domain annotation resource</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D493</fpage><lpage>D496</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx922</pub-id><pub-id pub-id-type="pmid">29040681</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo Bianco</surname> <given-names>C</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Régulier</surname> <given-names>E</given-names></name><name><surname>Lashuel</surname> <given-names>H</given-names></name><name><surname>Iwatsubo</surname> <given-names>T</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name><name><surname>Aebischer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of parkinson disease</article-title><source>Journal of Clinical Investigation</source><volume>118</volume><fpage>3087</fpage><lpage>3097</lpage><pub-id pub-id-type="doi">10.1172/JCI35781</pub-id><pub-id pub-id-type="pmid">18704197</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname> <given-names>KE</given-names></name><name><surname>Rizo</surname> <given-names>AN</given-names></name><name><surname>Tse</surname> <given-names>E</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Scull</surname> <given-names>NW</given-names></name><name><surname>Thwin</surname> <given-names>AC</given-names></name><name><surname>Lucius</surname> <given-names>AL</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Conformational plasticity of the ClpAP AAA+ protease couples protein unfolding and proteolysis</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>406</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0409-5</pub-id><pub-id pub-id-type="pmid">32313240</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname> <given-names>KC</given-names></name><name><surname>Kehm</surname> <given-names>V</given-names></name><name><surname>Carroll</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>O'Brien</surname> <given-names>P</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>Lee</surname> <given-names>VM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice</article-title><source>Science</source><volume>338</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1126/science.1227157</pub-id><pub-id pub-id-type="pmid">23161999</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname> <given-names>R</given-names></name><name><surname>Tkach</surname> <given-names>JM</given-names></name><name><surname>Vierling</surname> <given-names>E</given-names></name><name><surname>Glover</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evidence for an unfolding/threading mechanism for protein disaggregation by <italic>Saccharomyces cerevisiae</italic> Hsp104</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>29139</fpage><lpage>29146</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403777200</pub-id><pub-id pub-id-type="pmid">15128736</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname> <given-names>R</given-names></name><name><surname>Niggemann</surname> <given-names>M</given-names></name><name><surname>Glover</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Peptide and protein binding in the axial channel of Hsp104. insights into the mechanism of protein unfolding</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>30139</fpage><lpage>30150</lpage><pub-id pub-id-type="doi">10.1074/jbc.M804849200</pub-id><pub-id pub-id-type="pmid">18755692</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mack</surname> <given-names>KL</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>DeNizio</surname> <given-names>JE</given-names></name><name><surname>Yan</surname> <given-names>X</given-names></name><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Tariq</surname> <given-names>A</given-names></name><name><surname>Cupo</surname> <given-names>RR</given-names></name><name><surname>Castellano</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tuning Hsp104 specificity to selectively detoxify α-synuclein</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.15.043935</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname> <given-names>F</given-names></name><name><surname>Park</surname> <given-names>YM</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Buso</surname> <given-names>N</given-names></name><name><surname>Gur</surname> <given-names>T</given-names></name><name><surname>Madhusoodanan</surname> <given-names>N</given-names></name><name><surname>Basutkar</surname> <given-names>P</given-names></name><name><surname>Tivey</surname> <given-names>ARN</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Finn</surname> <given-names>RD</given-names></name><name><surname>Lopez</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The EMBL-EBI search and sequence analysis tools APIs in 2019</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W636</fpage><lpage>W641</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz268</pub-id><pub-id pub-id-type="pmid">30976793</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>March</surname> <given-names>ZM</given-names></name><name><surname>Sweeney</surname> <given-names>K</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>X</given-names></name><name><surname>Castellano</surname> <given-names>LM</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Gomes</surname> <given-names>E</given-names></name><name><surname>Sweeney</surname> <given-names>K</given-names></name><name><surname>Michalska</surname> <given-names>K</given-names></name><name><surname>Jedrzejczak</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapeutic genetic variation revealed in diverse Hsp104 homologs</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.25.008748</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>A</given-names></name><name><surname>Baker</surname> <given-names>TA</given-names></name><name><surname>Sauer</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Pore loops of the AAA+ ClpX machine grip substrates to drive translocation and unfolding</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>15</volume><fpage>1147</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1503</pub-id><pub-id pub-id-type="pmid">18931677</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattoo</surname> <given-names>RU</given-names></name><name><surname>Sharma</surname> <given-names>SK</given-names></name><name><surname>Priya</surname> <given-names>S</given-names></name><name><surname>Finka</surname> <given-names>A</given-names></name><name><surname>Goloubinoff</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hsp110 is a <italic>bona</italic> fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>21399</fpage><lpage>21411</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.479253</pub-id><pub-id pub-id-type="pmid">23737532</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAvoy</surname> <given-names>CZ</given-names></name><name><surname>Siegel</surname> <given-names>A</given-names></name><name><surname>Piszkiewicz</surname> <given-names>S</given-names></name><name><surname>Miaou</surname> <given-names>E</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Moradian</surname> <given-names>A</given-names></name><name><surname>Sweredoski</surname> <given-names>MJ</given-names></name><name><surname>Hess</surname> <given-names>S</given-names></name><name><surname>Shan</surname> <given-names>SO</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Two distinct sites of client protein interaction with the chaperone cpSRP43</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>8861</fpage><lpage>8873</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002215</pub-id><pub-id pub-id-type="pmid">29669809</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meinecke</surname> <given-names>M</given-names></name><name><surname>Wagner</surname> <given-names>R</given-names></name><name><surname>Kovermann</surname> <given-names>P</given-names></name><name><surname>Guiard</surname> <given-names>B</given-names></name><name><surname>Mick</surname> <given-names>DU</given-names></name><name><surname>Hutu</surname> <given-names>DP</given-names></name><name><surname>Voos</surname> <given-names>W</given-names></name><name><surname>Truscott</surname> <given-names>KN</given-names></name><name><surname>Chacinska</surname> <given-names>A</given-names></name><name><surname>Pfanner</surname> <given-names>N</given-names></name><name><surname>Rehling</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Tim50 maintains the permeability barrier of the mitochondrial inner membrane</article-title><source>Science</source><volume>312</volume><fpage>1523</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1126/science.1127628</pub-id><pub-id pub-id-type="pmid">16763150</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mészáros</surname> <given-names>B</given-names></name><name><surname>Simon</surname> <given-names>I</given-names></name><name><surname>Dosztányi</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Prediction of protein binding regions in disordered proteins</article-title><source>PLOS Computational Biology</source><volume>5</volume><elocation-id>e1000376</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000376</pub-id><pub-id pub-id-type="pmid">19412530</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mészáros</surname> <given-names>B</given-names></name><name><surname>Erdos</surname> <given-names>G</given-names></name><name><surname>Dosztányi</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W329</fpage><lpage>W337</lpage><pub-id pub-id-type="doi">10.1093/nar/gky384</pub-id><pub-id pub-id-type="pmid">29860432</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname> <given-names>H</given-names></name><name><surname>Muruganujan</surname> <given-names>A</given-names></name><name><surname>Ebert</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Thomas</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D419</fpage><lpage>D426</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1038</pub-id><pub-id pub-id-type="pmid">30407594</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalska</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>March</surname> <given-names>ZM</given-names></name><name><surname>Hatzos-Skintges</surname> <given-names>C</given-names></name><name><surname>Pintilie</surname> <given-names>G</given-names></name><name><surname>Bigelow</surname> <given-names>L</given-names></name><name><surname>Castellano</surname> <given-names>LM</given-names></name><name><surname>Miles</surname> <given-names>LJ</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Jedrzejczak</surname> <given-names>R</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Chiu</surname> <given-names>W</given-names></name><name><surname>Joachimiak</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structure of Calcarisporiella thermophila Hsp104 disaggregase that antagonizes diverse proteotoxic misfolding events</article-title><source>Structure</source><volume>27</volume><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.str.2018.11.001</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moczko</surname> <given-names>M</given-names></name><name><surname>Schönfisch,</surname> <given-names>B</given-names></name><name><surname>Voos</surname> <given-names>W</given-names></name><name><surname>Pfanner</surname> <given-names>N</given-names></name><name><surname>Rassow</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The mitochondrial ClpB homolog Hsp78 cooperates with matrix Hsp70 in maintenance of mitochondrial function</article-title><source>Journal of Molecular Biology</source><volume>254</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1995.0636</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogk</surname> <given-names>A</given-names></name><name><surname>Schlieker</surname> <given-names>C</given-names></name><name><surname>Strub</surname> <given-names>C</given-names></name><name><surname>Rist</surname> <given-names>W</given-names></name><name><surname>Weibezahn</surname> <given-names>J</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Roles of individual domains and conserved motifs of the AAA+ chaperone ClpB in Oligomerization, ATP hydrolysis, and chaperone activity</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>17615</fpage><lpage>17624</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209686200</pub-id><pub-id pub-id-type="pmid">12624113</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mokranjac</surname> <given-names>D</given-names></name><name><surname>Paschen</surname> <given-names>SA</given-names></name><name><surname>Kozany</surname> <given-names>C</given-names></name><name><surname>Prokisch</surname> <given-names>H</given-names></name><name><surname>Hoppins</surname> <given-names>SC</given-names></name><name><surname>Nargang</surname> <given-names>FE</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Hell</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tim50, a novel component of the TIM23 preprotein translocase of mitochondria</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>816</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg090</pub-id><pub-id pub-id-type="pmid">12574118</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mróz</surname> <given-names>D</given-names></name><name><surname>Wyszkowski</surname> <given-names>H</given-names></name><name><surname>Szablewski</surname> <given-names>T</given-names></name><name><surname>Zawieracz</surname> <given-names>K</given-names></name><name><surname>Dutkiewicz</surname> <given-names>R</given-names></name><name><surname>Bury</surname> <given-names>K</given-names></name><name><surname>Wortmann</surname> <given-names>SB</given-names></name><name><surname>Wevers</surname> <given-names>RA</given-names></name><name><surname>Ziętkiewicz</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CLPB (caseinolytic peptidase B homolog), the first mitochondrial protein refoldase associated with human disease</article-title><source>Biochimica Et Biophysica Acta (BBA) - General Subjects</source><volume>1864</volume><elocation-id>129512</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbagen.2020.129512</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>TX</given-names></name><name><surname>Jaru-Ampornpan</surname> <given-names>P</given-names></name><name><surname>Lam</surname> <given-names>VQ</given-names></name><name><surname>Cao</surname> <given-names>P</given-names></name><name><surname>Piszkiewicz</surname> <given-names>S</given-names></name><name><surname>Hess</surname> <given-names>S</given-names></name><name><surname>Shan</surname> <given-names>SO</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanism of an ATP-independent protein disaggregase: I. structure of a membrane protein aggregate reveals a mechanism of recognition by its chaperone</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>13420</fpage><lpage>13430</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.462812</pub-id><pub-id pub-id-type="pmid">23525109</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niaki</surname> <given-names>AG</given-names></name><name><surname>Sarkar</surname> <given-names>J</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Rhine</surname> <given-names>K</given-names></name><name><surname>Vidaurre</surname> <given-names>V</given-names></name><name><surname>Guy</surname> <given-names>B</given-names></name><name><surname>Hurst</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Koh</surname> <given-names>HR</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Fare</surname> <given-names>CM</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Myong</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-Linked FUS mutations</article-title><source>Molecular Cell</source><volume>77</volume><fpage>82</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.022</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>Kirstein</surname> <given-names>J</given-names></name><name><surname>Szlachcic</surname> <given-names>A</given-names></name><name><surname>Berynskyy</surname> <given-names>M</given-names></name><name><surname>Stank</surname> <given-names>A</given-names></name><name><surname>Stengel</surname> <given-names>F</given-names></name><name><surname>Arnsburg</surname> <given-names>K</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Scior</surname> <given-names>A</given-names></name><name><surname>Aebersold</surname> <given-names>R</given-names></name><name><surname>Guilbride</surname> <given-names>DL</given-names></name><name><surname>Wade</surname> <given-names>RC</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name><name><surname>Mayer</surname> <given-names>MP</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation</article-title><source>Nature</source><volume>524</volume><fpage>247</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nature14884</pub-id><pub-id pub-id-type="pmid">26245380</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname> <given-names>L</given-names></name><name><surname>Pardo</surname> <given-names>B</given-names></name><name><surname>Lasorsa</surname> <given-names>FM</given-names></name><name><surname>del Arco</surname> <given-names>A</given-names></name><name><surname>Kobayashi</surname> <given-names>K</given-names></name><name><surname>Iijima</surname> <given-names>M</given-names></name><name><surname>Runswick</surname> <given-names>MJ</given-names></name><name><surname>Walker</surname> <given-names>JE</given-names></name><name><surname>Saheki</surname> <given-names>T</given-names></name><name><surname>Satrústegui</surname> <given-names>J</given-names></name><name><surname>Palmieri</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Citrin and aralar1 are ca(2+)-stimulated aspartate/glutamate transporters in mitochondria</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>5060</fpage><lpage>5069</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.18.5060</pub-id><pub-id pub-id-type="pmid">11566871</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsell</surname> <given-names>DA</given-names></name><name><surname>Kowal</surname> <given-names>AS</given-names></name><name><surname>Singer</surname> <given-names>MA</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Protein disaggregation mediated by heat-shock protein Hsp104</article-title><source>Nature</source><volume>372</volume><fpage>475</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/372475a0</pub-id><pub-id pub-id-type="pmid">7984243</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschen</surname> <given-names>SA</given-names></name><name><surname>Rothbauer</surname> <given-names>U</given-names></name><name><surname>Káldi</surname> <given-names>K</given-names></name><name><surname>Bauer</surname> <given-names>MF</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Brunner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The role of the TIM8-13 complex in the import of Tim23 into mitochondria</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>6392</fpage><lpage>6400</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.23.6392</pub-id><pub-id pub-id-type="pmid">11101512</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patron</surname> <given-names>M</given-names></name><name><surname>Checchetto</surname> <given-names>V</given-names></name><name><surname>Raffaello</surname> <given-names>A</given-names></name><name><surname>Teardo</surname> <given-names>E</given-names></name><name><surname>Vecellio Reane</surname> <given-names>D</given-names></name><name><surname>Mantoan</surname> <given-names>M</given-names></name><name><surname>Granatiero</surname> <given-names>V</given-names></name><name><surname>Szabò</surname> <given-names>I</given-names></name><name><surname>De Stefani</surname> <given-names>D</given-names></name><name><surname>Rizzuto</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MICU1 and MICU2 finely tune the mitochondrial Ca2+ uniporter by exerting opposite effects on MCU activity</article-title><source>Molecular Cell</source><volume>53</volume><fpage>726</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.01.013</pub-id><pub-id pub-id-type="pmid">24560927</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Périer</surname> <given-names>F</given-names></name><name><surname>Radeke</surname> <given-names>CM</given-names></name><name><surname>Raab-Graham</surname> <given-names>KF</given-names></name><name><surname>Vandenberg</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Expression of a putative ATPase suppresses the growth defect of a yeast potassium transport mutant: identification of a mammalian member of the clp/HSP104 family</article-title><source>Gene</source><volume>152</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(94)00697-Q</pub-id><pub-id pub-id-type="pmid">7835694</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perocchi</surname> <given-names>F</given-names></name><name><surname>Gohil</surname> <given-names>VM</given-names></name><name><surname>Girgis</surname> <given-names>HS</given-names></name><name><surname>Bao</surname> <given-names>XR</given-names></name><name><surname>McCombs</surname> <given-names>JE</given-names></name><name><surname>Palmer</surname> <given-names>AE</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MICU1 encodes a mitochondrial EF hand protein required for ca(2+) uptake</article-title><source>Nature</source><volume>467</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nature09358</pub-id><pub-id pub-id-type="pmid">20693986</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin</surname> <given-names>V</given-names></name><name><surname>Régulier</surname> <given-names>E</given-names></name><name><surname>Abbas-Terki</surname> <given-names>T</given-names></name><name><surname>Hassig</surname> <given-names>R</given-names></name><name><surname>Brouillet</surname> <given-names>E</given-names></name><name><surname>Aebischer</surname> <given-names>P</given-names></name><name><surname>Luthi-Carter</surname> <given-names>R</given-names></name><name><surname>Déglon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease</article-title><source>Molecular Therapy</source><volume>15</volume><fpage>903</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1038/mt.sj.6300141</pub-id><pub-id pub-id-type="pmid">17375066</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plovanich</surname> <given-names>M</given-names></name><name><surname>Bogorad</surname> <given-names>RL</given-names></name><name><surname>Sancak</surname> <given-names>Y</given-names></name><name><surname>Kamer</surname> <given-names>KJ</given-names></name><name><surname>Strittmatter</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>AA</given-names></name><name><surname>Girgis</surname> <given-names>HS</given-names></name><name><surname>Kuchimanchi</surname> <given-names>S</given-names></name><name><surname>De Groot</surname> <given-names>J</given-names></name><name><surname>Speciner</surname> <given-names>L</given-names></name><name><surname>Taneja</surname> <given-names>N</given-names></name><name><surname>Oshea</surname> <given-names>J</given-names></name><name><surname>Koteliansky</surname> <given-names>V</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e55785</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0055785</pub-id><pub-id pub-id-type="pmid">23409044</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poveda-Huertes</surname> <given-names>D</given-names></name><name><surname>Matic</surname> <given-names>S</given-names></name><name><surname>Marada</surname> <given-names>A</given-names></name><name><surname>Habernig</surname> <given-names>L</given-names></name><name><surname>Licheva</surname> <given-names>M</given-names></name><name><surname>Myketin</surname> <given-names>L</given-names></name><name><surname>Gilsbach</surname> <given-names>R</given-names></name><name><surname>Tosal-Castano</surname> <given-names>S</given-names></name><name><surname>Papinski</surname> <given-names>D</given-names></name><name><surname>Mulica</surname> <given-names>P</given-names></name><name><surname>Kretz</surname> <given-names>O</given-names></name><name><surname>Kücükköse</surname> <given-names>C</given-names></name><name><surname>Taskin</surname> <given-names>AA</given-names></name><name><surname>Hein</surname> <given-names>L</given-names></name><name><surname>Kraft</surname> <given-names>C</given-names></name><name><surname>Büttner</surname> <given-names>S</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Vögtle</surname> <given-names>FN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An early mtUPR: redistribution of the nuclear transcription factor Rox1 to mitochondria protects against intramitochondrial proteotoxic aggregates</article-title><source>Molecular Cell</source><volume>77</volume><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.026</pub-id><pub-id pub-id-type="pmid">31630969</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pronicka</surname> <given-names>E</given-names></name><name><surname>Ropacka-Lesiak</surname> <given-names>M</given-names></name><name><surname>Trubicka</surname> <given-names>J</given-names></name><name><surname>Pajdowska</surname> <given-names>M</given-names></name><name><surname>Linke</surname> <given-names>M</given-names></name><name><surname>Ostergaard</surname> <given-names>E</given-names></name><name><surname>Saunders</surname> <given-names>C</given-names></name><name><surname>Horsch</surname> <given-names>S</given-names></name><name><surname>van Karnebeek</surname> <given-names>C</given-names></name><name><surname>Yaplito-Lee</surname> <given-names>J</given-names></name><name><surname>Distelmaier</surname> <given-names>F</given-names></name><name><surname>Õunap</surname> <given-names>K</given-names></name><name><surname>Rahman</surname> <given-names>S</given-names></name><name><surname>Castelle</surname> <given-names>M</given-names></name><name><surname>Kelleher</surname> <given-names>J</given-names></name><name><surname>Baris</surname> <given-names>S</given-names></name><name><surname>Iwanicka-Pronicka</surname> <given-names>K</given-names></name><name><surname>Steward</surname> <given-names>CG</given-names></name><name><surname>Ciara</surname> <given-names>E</given-names></name><name><surname>Wortmann</surname> <given-names>SB</given-names></name><collab>Additional individual contributors</collab></person-group><year iso-8601-date="2017">2017</year><article-title>A scoring system predicting the clinical course of CLPB defect based on the foetal and neonatal presentation of 31 patients</article-title><source>Journal of Inherited Metabolic Disease</source><volume>40</volume><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1007/s10545-017-0057-z</pub-id><pub-id pub-id-type="pmid">28687938</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Queitsch</surname> <given-names>C</given-names></name><name><surname>Hong</surname> <given-names>SW</given-names></name><name><surname>Vierling</surname> <given-names>E</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Heat shock protein 101 plays a crucial role in thermotolerance in Arabidopsis</article-title><source>The Plant Cell</source><volume>12</volume><fpage>479</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1105/tpc.12.4.479</pub-id><pub-id pub-id-type="pmid">10760238</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Rambaut</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><data-title>FigTree</data-title><source>GitHub</source><version designator="1. ">v1. 4</version><ext-link ext-link-type="uri" xlink:href="http://tree.bio.ed.ac.uk/software/figtree/">http://tree.bio.ed.ac.uk/software/figtree/</ext-link></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizo</surname> <given-names>AN</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Gates</surname> <given-names>SN</given-names></name><name><surname>Tse</surname> <given-names>E</given-names></name><name><surname>Bart</surname> <given-names>SM</given-names></name><name><surname>Castellano</surname> <given-names>LM</given-names></name><name><surname>DiMaio</surname> <given-names>F</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis for substrate gripping and translocation by the ClpB AAA+ disaggregase</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2393</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10150-y</pub-id><pub-id pub-id-type="pmid">31160557</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottgers</surname> <given-names>K</given-names></name><name><surname>Zufall</surname> <given-names>N</given-names></name><name><surname>Guiard</surname> <given-names>B</given-names></name><name><surname>Voos</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The ClpB homolog Hsp78 is required for the efficient degradation of proteins in the mitochondrial matrix</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>45829</fpage><lpage>45837</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207152200</pub-id><pub-id pub-id-type="pmid">12237310</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saita</surname> <given-names>S</given-names></name><name><surname>Nolte</surname> <given-names>H</given-names></name><name><surname>Fiedler</surname> <given-names>KU</given-names></name><name><surname>Kashkar</surname> <given-names>H</given-names></name><name><surname>Venne</surname> <given-names>AS</given-names></name><name><surname>Zahedi</surname> <given-names>RP</given-names></name><name><surname>Krüger</surname> <given-names>M</given-names></name><name><surname>Langer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARL mediates smac proteolytic maturation in mitochondria to promote apoptosis</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>318</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/ncb3488</pub-id><pub-id pub-id-type="pmid">28288130</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satyal</surname> <given-names>SH</given-names></name><name><surname>Schmidt</surname> <given-names>E</given-names></name><name><surname>Kitagawa</surname> <given-names>K</given-names></name><name><surname>Sondheimer</surname> <given-names>N</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name><name><surname>Kramer</surname> <given-names>JM</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Polyglutamine aggregates alter protein folding homeostasis in <italic>Caenorhabditis elegans</italic></article-title><source>PNAS</source><volume>97</volume><fpage>5750</fpage><lpage>5755</lpage><pub-id pub-id-type="doi">10.1073/pnas.100107297</pub-id><pub-id pub-id-type="pmid">10811890</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>C</given-names></name><name><surname>Smith</surname> <given-names>L</given-names></name><name><surname>Wibrand</surname> <given-names>F</given-names></name><name><surname>Ravn</surname> <given-names>K</given-names></name><name><surname>Bross</surname> <given-names>P</given-names></name><name><surname>Thiffault</surname> <given-names>I</given-names></name><name><surname>Christensen</surname> <given-names>M</given-names></name><name><surname>Atherton</surname> <given-names>A</given-names></name><name><surname>Farrow</surname> <given-names>E</given-names></name><name><surname>Miller</surname> <given-names>N</given-names></name><name><surname>Kingsmore</surname> <given-names>SF</given-names></name><name><surname>Ostergaard</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CLPB variants associated with autosomal-recessive mitochondrial disorder with cataract, neutropenia, epilepsy, and methylglutaconic aciduria</article-title><source>The American Journal of Human Genetics</source><volume>96</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.12.020</pub-id><pub-id pub-id-type="pmid">25597511</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saurer</surname> <given-names>M</given-names></name><name><surname>Ramrath</surname> <given-names>DJF</given-names></name><name><surname>Niemann</surname> <given-names>M</given-names></name><name><surname>Calderaro</surname> <given-names>S</given-names></name><name><surname>Prange</surname> <given-names>C</given-names></name><name><surname>Mattei</surname> <given-names>S</given-names></name><name><surname>Scaiola</surname> <given-names>A</given-names></name><name><surname>Leitner</surname> <given-names>A</given-names></name><name><surname>Bieri</surname> <given-names>P</given-names></name><name><surname>Horn</surname> <given-names>EK</given-names></name><name><surname>Leibundgut</surname> <given-names>M</given-names></name><name><surname>Boehringer</surname> <given-names>D</given-names></name><name><surname>Schneider</surname> <given-names>A</given-names></name><name><surname>Ban</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitoribosomal small subunit biogenesis in trypanosomes involves an extensive assembly machinery</article-title><source>Science</source><volume>365</volume><fpage>1144</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1126/science.aaw5570</pub-id><pub-id pub-id-type="pmid">31515389</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname> <given-names>M</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Langer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Hsp78, a clp homologue within mitochondria, can substitute for chaperone functions of mt-hsp70</article-title><source>The EMBO Journal</source><volume>14</volume><fpage>3434</fpage><lpage>3444</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1995.tb07349.x</pub-id><pub-id pub-id-type="pmid">7628444</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname> <given-names>M</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Langer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The molecular chaperone Hsp78 confers compartment-specific thermotolerance to mitochondria</article-title><source>The Journal of Cell Biology</source><volume>134</volume><fpage>1375</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1083/jcb.134.6.1375</pub-id><pub-id pub-id-type="pmid">8830768</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>TD</given-names></name><name><surname>Stephens</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Sequence logos: a new way to display consensus sequences</article-title><source>Nucleic Acids Research</source><volume>18</volume><fpage>6097</fpage><lpage>6100</lpage><pub-id pub-id-type="doi">10.1093/nar/18.20.6097</pub-id><pub-id pub-id-type="pmid">2172928</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scior</surname> <given-names>A</given-names></name><name><surname>Buntru</surname> <given-names>A</given-names></name><name><surname>Arnsburg</surname> <given-names>K</given-names></name><name><surname>Ast</surname> <given-names>A</given-names></name><name><surname>Iburg</surname> <given-names>M</given-names></name><name><surname>Juenemann</surname> <given-names>K</given-names></name><name><surname>Pigazzini</surname> <given-names>ML</given-names></name><name><surname>Mlody</surname> <given-names>B</given-names></name><name><surname>Puchkov</surname> <given-names>D</given-names></name><name><surname>Priller</surname> <given-names>J</given-names></name><name><surname>Wanker</surname> <given-names>EE</given-names></name><name><surname>Prigione</surname> <given-names>A</given-names></name><name><surname>Kirstein</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complete suppression of htt fibrilization and disaggregation of htt fibrils by a trimeric chaperone complex</article-title><source>The EMBO Journal</source><volume>37</volume><fpage>282</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.15252/embj.201797212</pub-id><pub-id pub-id-type="pmid">29212816</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seraphim</surname> <given-names>TV</given-names></name><name><surname>Houry</surname> <given-names>WA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AAA+ proteins</article-title><source>Current Biology</source><volume>30</volume><fpage>R251</fpage><lpage>R257</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2020.01.044</pub-id><pub-id pub-id-type="pmid">32208144</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hsp104: a weapon to combat diverse neurodegenerative disorders</article-title><source>Neurosignals</source><volume>16</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1159/000109760</pub-id><pub-id pub-id-type="pmid">18097161</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The mammalian disaggregase machinery: hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e26319</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026319</pub-id><pub-id pub-id-type="pmid">22022600</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Designer protein disaggregases to counter neurodegenerative disease</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>44</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2017.01.008</pub-id><pub-id pub-id-type="pmid">28208059</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers</article-title><source>Science</source><volume>304</volume><fpage>1793</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1126/science.1098007</pub-id><pub-id pub-id-type="pmid">15155912</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Lindquist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities</article-title><source>Molecular Cell</source><volume>23</volume><fpage>425</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.05.042</pub-id><pub-id pub-id-type="pmid">16885031</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Spiraling in control: structures and mechanisms of the Hsp104 disaggregase</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a034033</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a034033</pub-id><pub-id pub-id-type="pmid">30745294</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirrenberg</surname> <given-names>C</given-names></name><name><surname>Bauer</surname> <given-names>MF</given-names></name><name><surname>Guiard</surname> <given-names>B</given-names></name><name><surname>Neupert</surname> <given-names>W</given-names></name><name><surname>Brunner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Import of carrier proteins into the mitochondrial inner membrane mediated by Tim22</article-title><source>Nature</source><volume>384</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/384582a0</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname> <given-names>MG</given-names></name><name><surname>Crowther</surname> <given-names>RA</given-names></name><name><surname>Jakes</surname> <given-names>R</given-names></name><name><surname>Cairns</surname> <given-names>NJ</given-names></name><name><surname>Lantos</surname> <given-names>PL</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998a</year><article-title>Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies</article-title><source>Neuroscience Letters</source><volume>251</volume><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(98)00504-7</pub-id><pub-id pub-id-type="pmid">9726379</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname> <given-names>MG</given-names></name><name><surname>Crowther</surname> <given-names>RA</given-names></name><name><surname>Jakes</surname> <given-names>R</given-names></name><name><surname>Hasegawa</surname> <given-names>M</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998b</year><article-title>alpha-Synuclein in filamentous inclusions of lewy bodies from Parkinson's disease and dementia with lewy bodies</article-title><source>PNAS</source><volume>95</volume><fpage>6469</fpage><lpage>6473</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6469</pub-id><pub-id pub-id-type="pmid">9600990</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinazzi</surname> <given-names>M</given-names></name><name><surname>Radaelli</surname> <given-names>E</given-names></name><name><surname>Horré</surname> <given-names>K</given-names></name><name><surname>Arranz</surname> <given-names>AM</given-names></name><name><surname>Gounko</surname> <given-names>NV</given-names></name><name><surname>Agostinis</surname> <given-names>P</given-names></name><name><surname>Maia</surname> <given-names>TM</given-names></name><name><surname>Impens</surname> <given-names>F</given-names></name><name><surname>Morais</surname> <given-names>VA</given-names></name><name><surname>Lopez-Lluch</surname> <given-names>G</given-names></name><name><surname>Serneels</surname> <given-names>L</given-names></name><name><surname>Navas</surname> <given-names>P</given-names></name><name><surname>De Strooper</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PARL deficiency in mouse causes complex III defects, coenzyme Q depletion, and Leigh-like syndrome</article-title><source>PNAS</source><volume>116</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1073/pnas.1811938116</pub-id><pub-id pub-id-type="pmid">30578322</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Go</surname> <given-names>MS</given-names></name><name><surname>Sochor</surname> <given-names>MA</given-names></name><name><surname>Razzo</surname> <given-names>BM</given-names></name><name><surname>DeSantis</surname> <given-names>ME</given-names></name><name><surname>Gupta</surname> <given-names>K</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Hsp104 N-terminal domain enables disaggregase plasticity and potentiation</article-title><source>Molecular Cell</source><volume>57</volume><fpage>836</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.12.021</pub-id><pub-id pub-id-type="pmid">25620563</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Tariq</surname> <given-names>A</given-names></name><name><surname>Gurpinar</surname> <given-names>E</given-names></name><name><surname>Go</surname> <given-names>MS</given-names></name><name><surname>Sochor</surname> <given-names>MA</given-names></name><name><surname>Kan</surname> <given-names>ZY</given-names></name><name><surname>Mayne</surname> <given-names>L</given-names></name><name><surname>Englander</surname> <given-names>SW</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural and mechanistic insights into Hsp104 function revealed by synchrotron X-ray footprinting</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>1517</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.011577</pub-id><pub-id pub-id-type="pmid">31882541</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname> <given-names>R</given-names></name><name><surname>Wanschers</surname> <given-names>BF</given-names></name><name><surname>Nabuurs</surname> <given-names>SB</given-names></name><name><surname>Nouws</surname> <given-names>J</given-names></name><name><surname>Nijtmans</surname> <given-names>LG</given-names></name><name><surname>Huynen</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>NDUFB7 and NDUFA8 are located at the intermembrane surface of complex I</article-title><source>FEBS Letters</source><volume>585</volume><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2011.01.046</pub-id><pub-id pub-id-type="pmid">21310150</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariq</surname> <given-names>A</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Noll</surname> <given-names>MM</given-names></name><name><surname>Torrente</surname> <given-names>MP</given-names></name><name><surname>Mack</surname> <given-names>KL</given-names></name><name><surname>Murillo</surname> <given-names>OH</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain</article-title><source>FEMS Yeast Research</source><volume>18</volume><elocation-id>foy042</elocation-id><pub-id pub-id-type="doi">10.1093/femsyr/foy042</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariq</surname> <given-names>A</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Hesketh</surname> <given-names>CD</given-names></name><name><surname>Carman</surname> <given-names>PJ</given-names></name><name><surname>Mack</surname> <given-names>KL</given-names></name><name><surname>Weitzman</surname> <given-names>R</given-names></name><name><surname>Gambogi</surname> <given-names>C</given-names></name><name><surname>Hernandez Murillo</surname> <given-names>OA</given-names></name><name><surname>Sweeny</surname> <given-names>EA</given-names></name><name><surname>Gurpinar</surname> <given-names>E</given-names></name><name><surname>Yokom</surname> <given-names>AL</given-names></name><name><surname>Gates</surname> <given-names>SN</given-names></name><name><surname>Yee</surname> <given-names>K</given-names></name><name><surname>Sudesh</surname> <given-names>S</given-names></name><name><surname>Stillman</surname> <given-names>J</given-names></name><name><surname>Rizo</surname> <given-names>AN</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mining disaggregase sequence space to safely counter TDP-43, FUS, and α-Synuclein proteotoxicity</article-title><source>Cell Reports</source><volume>28</volume><fpage>2080</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.069</pub-id><pub-id pub-id-type="pmid">31433984</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Gene Ontology Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>The gene ontology resource: 20 years and still GOing strong</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D330</fpage><lpage>D338</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1055</pub-id><pub-id pub-id-type="pmid">30395331</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkach</surname> <given-names>JM</given-names></name><name><surname>Glover</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nucleocytoplasmic trafficking of the molecular chaperone Hsp104 in unstressed and heat-shocked cells</article-title><source>Traffic</source><volume>9</volume><fpage>39</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2007.00666.x</pub-id><pub-id pub-id-type="pmid">17973656</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrente</surname> <given-names>MP</given-names></name><name><surname>Chuang</surname> <given-names>E</given-names></name><name><surname>Noll</surname> <given-names>MM</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Go</surname> <given-names>MS</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanistic insights into Hsp104 potentiation</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>5101</fpage><lpage>5115</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.707976</pub-id><pub-id pub-id-type="pmid">26747608</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrente</surname> <given-names>MP</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The metazoan protein disaggregase and amyloid depolymerase system: hsp110, Hsp70, Hsp40, and small heat shock proteins</article-title><source>Prion</source><volume>7</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.4161/pri.27531</pub-id><pub-id pub-id-type="pmid">24401655</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzagoloff</surname> <given-names>A</given-names></name><name><surname>Capitanio</surname> <given-names>N</given-names></name><name><surname>Nobrega</surname> <given-names>MP</given-names></name><name><surname>Gatti</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Cytochrome oxidase assembly in yeast requires the product of COX11, a homolog of the P. denitrificans protein encoded by ORF3</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>2759</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07463.x</pub-id><pub-id pub-id-type="pmid">2167832</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vacher</surname> <given-names>C</given-names></name><name><surname>Garcia-Oroz</surname> <given-names>L</given-names></name><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>14</volume><fpage>3425</fpage><lpage>3433</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi372</pub-id><pub-id pub-id-type="pmid">16204350</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Janowsky</surname> <given-names>B</given-names></name><name><surname>Major</surname> <given-names>T</given-names></name><name><surname>Knapp</surname> <given-names>K</given-names></name><name><surname>Voos</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The disaggregation activity of the mitochondrial ClpB homolog Hsp78 maintains Hsp70 function during heat stress</article-title><source>Journal of Molecular Biology</source><volume>357</volume><fpage>793</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.01.008</pub-id><pub-id pub-id-type="pmid">16460754</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voos</surname> <given-names>W</given-names></name><name><surname>Röttgers</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Molecular chaperones as essential mediators of mitochondrial biogenesis</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1592</volume><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0167-4889(02)00264-1</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname> <given-names>EW</given-names></name><name><surname>Kear-Scott</surname> <given-names>JL</given-names></name><name><surname>Pilipenko</surname> <given-names>EV</given-names></name><name><surname>Schwartz</surname> <given-names>MH</given-names></name><name><surname>Laskowski</surname> <given-names>PR</given-names></name><name><surname>Rojek</surname> <given-names>AE</given-names></name><name><surname>Katanski</surname> <given-names>CD</given-names></name><name><surname>Riback</surname> <given-names>JA</given-names></name><name><surname>Dion</surname> <given-names>MF</given-names></name><name><surname>Franks</surname> <given-names>AM</given-names></name><name><surname>Airoldi</surname> <given-names>EM</given-names></name><name><surname>Pan</surname> <given-names>T</given-names></name><name><surname>Budnik</surname> <given-names>BA</given-names></name><name><surname>Drummond</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reversible, specific, active aggregates of endogenous proteins assemble upon heat stress</article-title><source>Cell</source><volume>162</volume><fpage>1286</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.041</pub-id><pub-id pub-id-type="pmid">26359986</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkening</surname> <given-names>A</given-names></name><name><surname>Rüb</surname> <given-names>C</given-names></name><name><surname>Sylvester</surname> <given-names>M</given-names></name><name><surname>Voos</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Analysis of heat-induced protein aggregation in human mitochondria</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>11537</fpage><lpage>11552</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002122</pub-id><pub-id pub-id-type="pmid">29895621</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname> <given-names>MR</given-names></name><name><surname>Gasteiger</surname> <given-names>E</given-names></name><name><surname>Bairoch</surname> <given-names>A</given-names></name><name><surname>Sanchez</surname> <given-names>JC</given-names></name><name><surname>Williams</surname> <given-names>KL</given-names></name><name><surname>Appel</surname> <given-names>RD</given-names></name><name><surname>Hochstrasser</surname> <given-names>DF</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Protein identification and analysis tools in the ExPASy server</article-title><source>Methods in Molecular Biology</source><volume>112</volume><fpage>531</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1385/1-59259-584-7:531</pub-id><pub-id pub-id-type="pmid">10027275</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortmann</surname> <given-names>SB</given-names></name><name><surname>Ziętkiewicz</surname> <given-names>S</given-names></name><name><surname>Kousi</surname> <given-names>M</given-names></name><name><surname>Szklarczyk</surname> <given-names>R</given-names></name><name><surname>Haack</surname> <given-names>TB</given-names></name><name><surname>Gersting</surname> <given-names>SW</given-names></name><name><surname>Muntau</surname> <given-names>AC</given-names></name><name><surname>Rakovic</surname> <given-names>A</given-names></name><name><surname>Renkema</surname> <given-names>GH</given-names></name><name><surname>Rodenburg</surname> <given-names>RJ</given-names></name><name><surname>Strom</surname> <given-names>TM</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Rubio-Gozalbo</surname> <given-names>ME</given-names></name><name><surname>Chrusciel</surname> <given-names>E</given-names></name><name><surname>Distelmaier</surname> <given-names>F</given-names></name><name><surname>Golzio</surname> <given-names>C</given-names></name><name><surname>Jansen</surname> <given-names>JH</given-names></name><name><surname>van Karnebeek</surname> <given-names>C</given-names></name><name><surname>Lillquist</surname> <given-names>Y</given-names></name><name><surname>Lücke</surname> <given-names>T</given-names></name><name><surname>Õunap</surname> <given-names>K</given-names></name><name><surname>Zordania</surname> <given-names>R</given-names></name><name><surname>Yaplito-Lee</surname> <given-names>J</given-names></name><name><surname>van Bokhoven</surname> <given-names>H</given-names></name><name><surname>Spelbrink</surname> <given-names>JN</given-names></name><name><surname>Vaz</surname> <given-names>FM</given-names></name><name><surname>Pras-Raves</surname> <given-names>M</given-names></name><name><surname>Ploski</surname> <given-names>R</given-names></name><name><surname>Pronicka</surname> <given-names>E</given-names></name><name><surname>Klein</surname> <given-names>C</given-names></name><name><surname>Willemsen</surname> <given-names>MA</given-names></name><name><surname>de Brouwer</surname> <given-names>AP</given-names></name><name><surname>Prokisch</surname> <given-names>H</given-names></name><name><surname>Katsanis</surname> <given-names>N</given-names></name><name><surname>Wevers</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder</article-title><source>The American Journal of Human Genetics</source><volume>96</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.12.013</pub-id><pub-id pub-id-type="pmid">25597510</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wortmann</surname> <given-names>SB</given-names></name><name><surname>Wevers</surname> <given-names>RA</given-names></name><name><surname>de Brouwer</surname> <given-names>APM</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>CLPB Deficiency</chapter-title><person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P</given-names></name><name><surname>Ardinger</surname> <given-names>H. H</given-names></name><name><surname>Pagon</surname> <given-names>R. A</given-names></name><name><surname>Wallace</surname> <given-names>S. E</given-names></name><name><surname>Bean</surname> <given-names>L. J. H</given-names></name><name><surname>Stephens</surname> <given-names>K</given-names></name><name><surname>Amemiya</surname> <given-names>A</given-names></name></person-group><source>GeneReviews(R)</source><publisher-name>University of Washington Press</publisher-name><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>H</given-names></name><name><surname>Esaki</surname> <given-names>M</given-names></name><name><surname>Kanamori</surname> <given-names>T</given-names></name><name><surname>Tamura</surname> <given-names>Y</given-names></name><name><surname>Nishikawa</surname> <given-names>S</given-names></name><name><surname>Endo</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Tim50 is a subunit of the TIM23 complex that links protein translocation across the outer and inner mitochondrial membranes</article-title><source>Cell</source><volume>111</volume><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01053-X</pub-id><pub-id pub-id-type="pmid">12437925</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname> <given-names>M</given-names></name><name><surname>Terada</surname> <given-names>K</given-names></name><name><surname>Mori</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>AIP is a mitochondrial import mediator that binds to both import receptor Tom20 and preproteins</article-title><source>The Journal of Cell Biology</source><volume>163</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1083/jcb.200305051</pub-id><pub-id pub-id-type="pmid">14557246</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname> <given-names>K</given-names></name><name><surname>Clatterbuck-Soper</surname> <given-names>SF</given-names></name><name><surname>Jackrel</surname> <given-names>ME</given-names></name><name><surname>Shorter</surname> <given-names>J</given-names></name><name><surname>Mili</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>1015</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1083/jcb.201608022</pub-id><pub-id pub-id-type="pmid">28298410</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshinaka</surname> <given-names>T</given-names></name><name><surname>Kosako</surname> <given-names>H</given-names></name><name><surname>Yoshizumi</surname> <given-names>T</given-names></name><name><surname>Furukawa</surname> <given-names>R</given-names></name><name><surname>Hirano</surname> <given-names>Y</given-names></name><name><surname>Kuge</surname> <given-names>O</given-names></name><name><surname>Tamada</surname> <given-names>T</given-names></name><name><surname>Koshiba</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of mitochondrial scaffolds by prohibitin complexes: insight into a role of the Coiled-Coil region</article-title><source>iScience</source><volume>19</volume><fpage>1065</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2019.08.056</pub-id><pub-id pub-id-type="pmid">31522117</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshizawa</surname> <given-names>T</given-names></name><name><surname>Ali</surname> <given-names>R</given-names></name><name><surname>Jiou</surname> <given-names>J</given-names></name><name><surname>Fung</surname> <given-names>HYJ</given-names></name><name><surname>Burke</surname> <given-names>KA</given-names></name><name><surname>Kim</surname> <given-names>SJ</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Peeples</surname> <given-names>WB</given-names></name><name><surname>Saltzberg</surname> <given-names>D</given-names></name><name><surname>Soniat</surname> <given-names>M</given-names></name><name><surname>Baumhardt</surname> <given-names>JM</given-names></name><name><surname>Oldenbourg</surname> <given-names>R</given-names></name><name><surname>Sali</surname> <given-names>A</given-names></name><name><surname>Fawzi</surname> <given-names>NL</given-names></name><name><surname>Rosen</surname> <given-names>MK</given-names></name><name><surname>Chook</surname> <given-names>YM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites</article-title><source>Cell</source><volume>173</volume><fpage>693</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.003</pub-id><pub-id pub-id-type="pmid">29677513</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Antibody</td><td>Mouse monoclonal α-α-synuclein (SYN211)</td><td>ThermoFisher Scientific</td><td>AHB0261; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10978319">AB_10978319</ext-link></td><td>(1:500 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal α-CLPB (Skd3)</td><td>abcam</td><td>ab235349; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2847899">AB_2847899</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal α-CLPB (Skd3)</td><td>abcam</td><td>ab76179; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1310087">AB_1310087</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal α-CLPB (Skd3)</td><td>abcam</td><td>ab87253; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1952530">AB_1952530</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal α-CLPB (Skd3)</td><td>Proteintech</td><td>15743–1-AP; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2847900">AB_2847900</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal <break/>α-COXIV</td><td>abcam</td><td valign="bottom">ab14744; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_301443">AB_301443</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Mouse monoclonal α-GAPDH</td><td>abcam</td><td>ab8245; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2107448">AB_2107448</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal α-HAX1</td><td>abcam</td><td valign="bottom">ab137613; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2847902">AB_2847902</ext-link></td><td>(1:500 dilution)</td></tr><tr><td>Antibody</td><td>Rabbit polyclonal <break/>α-MICU2</td><td>abcam</td><td valign="bottom">ab101465; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10711219">AB_10711219</ext-link></td><td>(1:1000 dilution)</td></tr><tr><td>Antibody</td><td>IRDye 680RD Goat anti-Rabbit IgG Secondary Antibody</td><td>Li-Cor</td><td valign="bottom">926–68071; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10956166">AB_10956166</ext-link></td><td>(1:2500 dilution)</td></tr><tr><td>Antibody</td><td>IRDye 800CW Goat anti-Mouse IgG Secondary Antibody</td><td>Li-Cor</td><td valign="bottom">926–32210; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_621842">AB_621842</ext-link></td><td>(1:2500 dilution)</td></tr><tr><td>Cell line (<italic>Escherichia coli</italic>)</td><td>BL21-CodonPlus (DE3) <break/>-RIL competent cells</td><td>Agilent</td><td>230245</td><td>Chemically competent cells</td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human HAP1 Knockout Cell Lines - WT</td><td>Horizon Discovery</td><td>HZGHC81570;; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_Y019">CVCL_Y019</ext-link></td><td>Human control cell line. The HAP1 cell line was bought directly from Horizon Discovery and has been control quality checked by the vendor.</td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human HAP1 Knockout Cell Lines - CLPB</td><td>Horizon Discovery</td><td>HZGHC007326c001</td><td>Human knockout cell line. The HAP1 ClpB knockout cell line was bought directly from Horizon Discovery and has been control quality checked by the vendor.</td></tr><tr><td>Commercial assay or kit</td><td>ATPase Activity Kit (Colorimetric)</td><td>Innova Biosciencens</td><td>601–0120</td><td/></tr><tr><td>Commercial assay or kit</td><td>Luciferase Assay Reagent</td><td>Promega</td><td>E1483</td><td/></tr><tr><td>Chemical compound, drug</td><td>Creatine phosphate</td><td>Roche</td><td>10621722001</td><td/></tr><tr><td>Chemical compound, drug</td><td>ADP</td><td>MP Biomedicals</td><td>150260</td><td/></tr><tr><td>Chemical compound, drug</td><td>AMPPNP</td><td>Roche</td><td>10102547001</td><td/></tr><tr><td>Chemical compound, drug</td><td>ATP</td><td>Sigma-Aldrich</td><td>A3377</td><td/></tr><tr><td>Chemical compound, drug</td><td>ATPγS</td><td>Roche</td><td>10102342001</td><td/></tr><tr><td>Chemical compound, drug</td><td>cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail</td><td>Sigma-Aldrich</td><td>4693159001</td><td/></tr><tr><td>Chemical compound, drug</td><td>Pepstatin A, microbial,≥90% (HPLC)</td><td>Sigma-Aldrich</td><td>P5318</td><td/></tr><tr><td>Chemical compound, drug</td><td>Protease Inhibitor Cocktail (mammalian)</td><td>Sigma-Aldrich</td><td>P8340</td><td/></tr><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td><italic>CLPB</italic></td><td>NA</td><td>HGNC:30664</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>α-synuclein fibrils</td><td><xref ref-type="bibr" rid="bib64">Luk et al., 2012</xref></td><td/><td>Preformed α-synuclein fibrils were a gift from Kelvin Luk.</td></tr><tr><td>Peptide, recombinant protein</td><td>β-casein</td><td>Sigma-Aldrich</td><td>C6905</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>Creatine kinase</td><td>Roche</td><td>10127566001</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>Firefly luciferase</td><td>Sigma-Aldrich</td><td>L9506</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>Hdj1</td><td><xref ref-type="bibr" rid="bib77">Michalska et al., 2019</xref></td><td/><td/></tr><tr><td>Peptide, recombinant protein</td><td>Hsc70</td><td><xref ref-type="bibr" rid="bib77">Michalska et al., 2019</xref></td><td/><td/></tr><tr><td>Peptide, recombinant protein</td><td>Hsp104</td><td><xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref> and <xref ref-type="bibr" rid="bib50">Jackrel et al., 2014</xref></td><td/><td/></tr><tr><td>Peptide, recombinant protein</td><td>Lysozyme</td><td>Sigma-Aldrich</td><td>L6876</td><td/></tr><tr><td>Peptide, recombinant protein</td><td><sub>MPP</sub>Skd3</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>MPP</sub>Skd3<sup>K387A</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>MPP</sub>Skd3<sup>E455Q</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>MPP</sub>Skd3<sup>Y430A</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>K387A</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>E455Q</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>Y430A</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>T268M</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>R475Q</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>A591V</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td><sub>PARL</sub>Skd3<sup>R650P</sup></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td>Skd3<sub>ANK</sub></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Peptide, recombinant protein</td><td>Skd3<sub>NBD</sub></td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td>Hdj1 in pE-SUMO</td><td><xref ref-type="bibr" rid="bib77">Michalska et al., 2019</xref></td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>Hsc70 in pE-SUMO</td><td><xref ref-type="bibr" rid="bib77">Michalska et al., 2019</xref></td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>Hsp104 in pNOTAG</td><td><xref ref-type="bibr" rid="bib24">DeSantis et al., 2012</xref> and <xref ref-type="bibr" rid="bib50">Jackrel et al., 2014</xref></td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td><sub>MPP</sub>Skd3 in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>MPP</sub>Skd3<sup>K387A</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>MPP</sub>Skd3<sup>E455Q</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>MPP</sub>Skd3<sup>Y430A</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3 in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>K387A</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>E455Q</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>Y430A</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>T268M</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>R475Q</sup> in pMAL <break/>C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>A591V</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td><sub>PARL</sub>Skd3<sup>R650P</sup> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td>Skd3<sub>ANK</sub> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Recombinant DNA reagent</td><td>Skd3<sub>NBD</sub> in pMAL C2 with TEV site</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>ClpA (<italic>Escherichia coli</italic>)</td><td>This study</td><td>UniProtKB:P0ABH9</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>ClpB (<italic>Escherichia coli</italic>)</td><td>This study</td><td>UniProtKB:P63284</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>ClpC (<italic>Staphylococcus aureus</italic>)</td><td>This study</td><td>UniProtKB:Q2G0P5</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Hsp104 (<italic>Saccharomyces cerevisiae</italic>)</td><td>This study</td><td>UniProtKB:P31539</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Hsp78 (<italic>Saccharomyces cerevisiae</italic>)</td><td>This study</td><td>UniProtKB:P33416</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>HAX1 (<italic>Homo sapiens</italic>)</td><td>This study</td><td>UniProtKB:O00165</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Ailuropoda melanoleuca</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Anolis carolinensis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Bos taurus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Callithrix jacchus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Callorhinus ursinus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Canis lupus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Capra hircus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Carlito syrichta</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Cebus capucinus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Ceratotherium simum</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Cercocebus atys</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Chlorocebus sabaeus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Colobus angolensis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Danio rerio</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Equus asinus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Equus caballus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Equus przewalskii</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Felis catus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Geospiza fortis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Gorilla gorilla</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Gulo gulo</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Grammomys surdaster</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Homo sapiens)</italic></td><td>This study</td><td>UniProtKB:Q9H078</td><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Macaca fascicularis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Macaca mulatta</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Macaca nemestrina</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Mandrillus leucophaeus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Microcebus murinus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Microtus ochrogaster</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Monosigia brevicollis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Mus musculus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Mustela putorius</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Nomascus leucogenys</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Nothobranchius rachovii</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Odobenus rosmarus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Orycteropus afer</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Pan paniscus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Pan troglodyte</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Panthera tigris</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Papio anubis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent <break/></td><td>Skd3 <break/>(<italic>Piliocolobus tephrosceles</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Pongo abelii</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Propithecus coquereli</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Puma concolor</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Rattus norvegicus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Rhinopithecus bieti</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Rhinopithecus roxellana</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Rousettus aegyptiacus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Sus scrofa</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Theropithecus gelada</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Trachymyrmex septentrionalis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Trichinella papuae</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Ursus arctos</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Ursus maritimus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Xenopus laevis</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Sequence-based reagent</td><td>Skd3 (<italic>Zalophus californianus</italic>)</td><td>This study</td><td/><td>Full description can be found in Materials and methods: Purification of Skd3</td></tr><tr><td>Software, algorithm</td><td>BOXSHADE</td><td><xref ref-type="bibr" rid="bib48">Hofmann and Baron, 1996</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Clusal Omega</td><td><xref ref-type="bibr" rid="bib68">Madeira et al., 2019</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>EXPASY ProtParam</td><td><xref ref-type="bibr" rid="bib59">Kyte and Doolittle, 1982</xref>; <xref ref-type="bibr" rid="bib133">Wilkins et al., 1999</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>FigTree</td><td><xref ref-type="bibr" rid="bib96">Rambaut, 2012</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Gene Ontology (GO)</td><td><xref ref-type="bibr" rid="bib3">Ashburner et al., 2000</xref>; <xref ref-type="bibr" rid="bib76">Mi et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">The Gene Ontology Consortium, 2019</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>IUPRED</td><td><xref ref-type="bibr" rid="bib75">Mészáros et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Mészáros et al., 2009</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PhyloPic</td><td><ext-link ext-link-type="uri" xlink:href="http://phylopic.org/">http://phylopic.org/</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Prism 8</td><td>GraphPad</td><td/><td/></tr><tr><td>Software, algorithm</td><td>WebLogo</td><td><ext-link ext-link-type="uri" xlink:href="https://weblogo.berkeley.edu/logo.cgi">https://weblogo.</ext-link> <break/><ext-link ext-link-type="uri" xlink:href="https://weblogo.berkeley.edu/logo.cgi">berkeley.edu/logo.cgi</ext-link></td><td/><td/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55279.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Berger</surname><given-names>James M</given-names></name><role>Reviewing Editor</role><aff><institution>Johns Hopkins University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Glynn</surname><given-names>Steven</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Skd3 is a mitochondrial AAA+ enzyme whose function has been poorly-understood. The authors reveal that Skd3 is capable of both reactivating a model aggregated luciferase substrate and solubilizing α-synuclein in vitro. The in vitro activity of Skd3 is shown to be enhanced by the proteolytic cleavage of an autoinhibitory peptide, which is removed by the PARL protease in mitochondria. Useful mechanistic insights are also provided into some of the known disease-associated mutations in Skd3. Overall, the findings are of significant interest, as they address long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Skd3 is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Steven Glynn (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Skd3 is a mitochondrial AAA+ enzyme whose function has been poorly-understood. The authors reveal that Skd3 is capable of reactivating a model luciferase aggregate and solubilizing α-synuclein in vitro. The in vitro activity of Skd3 is shown to be enhanced by the proteolytic cleavage of an autoinhibitory peptide, which is removed by the PARL protease in mitochondria. Loss of SKD3 in human mitochondria is found to decrease the solubility of several specific proteins in the intermembrane space, although it is unclear whether this is a direct effect. The experiments employed are straight-forward and a full analysis of SKD3 activity, including the identify of its physiological substrates, will require further studies.</p><p>The study is carefully done, and the manuscript is well-written. Although a recent study reported a similar finding (i.e., that Skd3 serves as disaggregase), the present study is substantially more thorough and validates at least some of the in vitro findings in the cellular context. The work also provides useful mechanistic insights into some of the known disease-associated mutations in Skd3. Overall, the findings are of significant interest in addressing long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78. This said, the study falls short on demonstrating true disaggregation activity in vitro and in vivo, behaviors that ideally would need to be validated before publication is warranted.</p><p>While this review was being finalized, the complexities of COVID-19 emerged. Given these recent developments, the reviewers recognize that the additional experiments they initially requested may not be possible. We would therefore ask that the authors first read the 'original' review for a sense of the issues raised by the reviewers, and then the 'updated' review, which follows for a revised set of requests.</p><p>Essential revisions:</p><p>1) The authors demonstrate that Skd3 reactivates thermally inactivated luciferase but do not show directly that Skd3 actually dissociates luciferase aggregates (the solubilization of α-synuclein in Figure 4 is insufficient to demonstrate such an activity because the experiments never start with the isolated fibrils only and no equivalent experiments are shown with luciferase). An in vitro test for disaggregation activity (e.g., spinning down and quantifying aggregates as a function of Skd3 activity) is necessary to validate the primary point of the manuscript.</p><p>2) Similar to (1), the authors should show that Skd3 is able to disaggregate proteins in vivo (the increased solubility of HAX1 in Figure 7 is insufficient to demonstrate such an activity because it cannot distinguish between whether Skd3 resolves aggregation or prevents aggregation from happening in the first place). One approach that might be of use is that of Janowsky et al., who showed that mitochondrial Hsp78 was to induce thermal aggregation of an imported protein in purified mitochondria and then monitor disaggregation +/- Hsp78 (von Janowsky et al., 2006). Other work by Liberek provides some alternative approaches.</p><p>3) The changes in mitochondrial protein solubility observed in SKD3 knockout cells could be caused by loss of SKD3 disaggregase activity on specific proteins or secondary defects in protein import or membrane integration leading to accumulation of misfolded/uninserted proteins in the IMS. The authors should address this question in the Discussion.</p><p>4) The loss of ATPase and disaggregase activity seen for the isolated NBD domain (SKD3NBD) could be explained by disassembly of SKD3 hexamers in the absence of the ankyrin domains. The authors should include information on whether these constructs form stable hexamers.</p><p>5) Figures 2C/E and 3C/E: Instead of normalized data, it is important to show the real reactivation data. Are 1% or 50% of luciferase molecules reactivatable with Skd3 in this set up?</p><p>6) No direct evidence has been presented that the pore-loop Y430 makes direct contact with the substrate, hence it seems an overreach to claim that the conserved tyrosine binds the substrate. This statement should be qualified or better supported.</p><p>7) Some additional mutants should be tested before concluding that disaggregase activity correlates with disease severity (a term that needs to be defined). Otherwise, this claim should be toned down.</p><p>Updated Essential revisions in light of COVID-19:</p><p>1) Please address as many points as possible raised in the original summary.</p><p>2) Regarding Essential revision #1, above – the in vitro data can be strengthened by improved data analysis and discussion of the limitations, which should be possible without additional experiments. Specifically, the amount of luciferase as a % of total activity prior to aggregation should be reported to help support the idea that Skd3 is a robust disaggregase. Please also comment on the estimated fraction of α-synuclein present in fibrils in at the start of the in vitro disaggregation assay.</p><p>3) Regarding Essential revision #2, above – the fact that the in vivo experiments in Figure 7 do not distinguish between disaggregation and maintaining protein solubility should be directly addressed in the Discussion.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55279.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>[…] Overall, the findings are of significant interest in addressing long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78. This said, the study falls short on demonstrating true disaggregation activity in vitro and in vivo, behaviors that ideally would need to be validated before publication is warranted.</p></disp-quote><p>We respectfully disagree with the reviewers concerning the in vitro data. We have established that Skd3 is a potent disaggregase in vitro, capable of dissolving disordered aggregates and amyloid (please see further details below). We also establish that Skd3 maintains the solubility of many mitochondrial proteins in vivo, which is highly consistent with its potent disaggregase activity defined in vitro.</p><disp-quote content-type="editor-comment"><p>While this review was being finalized, the complexities of COVID-19 emerged. Given these recent developments, the reviewers recognize that the additional experiments they initially requested may not be possible. We would therefore ask that the authors first read the 'original' review for a sense of the issues raised by the reviewers, and then the 'updated' review, which follows for a revised set of requests.</p></disp-quote><p>We thank the reviewers for their thoughtful suggestions, which have helped us to improve the manuscript. We also appreciate the recognition of the difficulties in pursuing further experiments at this time during the pandemic. Indeed, at the time of finalizing this response (May 6<sup>th</sup>), it is not clear when UPenn will reopen labs (indeed Philadelphia is under stay at home orders until June 4<sup>th</sup>). Please find our response to both the original and updated reviews below.</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors demonstrate that Skd3 reactivates thermally inactivated luciferase but do not show directly that Skd3 actually dissociates luciferase aggregates.</p></disp-quote><p>We did not use thermally inactivated luciferase; rather, we used a long-established protocol (first developed in Susan Lindquist’s lab) for generating large chemically denatured, luciferase aggregates, which is a gold standard for the study of protein disaggregases (DeSantis et al., 2012; Glover and Lindquist, 1998). Thus, firefly luciferase was chemically denatured with 8M urea and then rapidly diluted 100-fold into a physiological buffer (DeSantis et al., 2012; Glover and Lindquist, 1998). This protocol yields aggregated luciferase species of predominantly ∼500-2,000kDa or greater in size and very few luciferase species smaller than ~400kDa can be detected (Glover and Lindquist, 1998). Importantly, these samples are devoid of misfolded, monomeric luciferase (Glover and Lindquist, 1998). Reactivation of luciferase in this assay is thus primarily achieved by the extraction and subsequent refolding of monomeric luciferase (M<sub>w</sub>~61kDa) from large aggregated structures (∼500-2,000kDa or larger) (Glover and Lindquist, 1998). Hence, in this assay, luciferase reactivation is an accurate proxy for luciferase disaggregation. We now emphasize this point in the subsection “Skd3 couples ATP hydrolysis to protein disaggregation and reactivation”.</p><p>Importantly, it has also been established that Hsp70 and Hsp40 are unable to disaggregate and reactivate luciferase found in these large aggregated structures (∼500-2,000kDa or larger), but can disaggregate and reactivate luciferase trapped in aggregated species smaller than 400kDa, albeit with a low yield (Glover and Lindquist, 1998). Indeed, only the combination of Hsp104, Hsp70, and Hsp40 can disaggregate and reactivate luciferase trapped in larger aggregates greater than ∼500kDa in size (Glover and Lindquist, 1998). Throughout our studies, we include the essential negative control of Hsp70 and Hsp40 in our luciferase disaggregation/reactivation assays. We would expect to see no reactivation of luciferase by Hsp70 and Hsp40 if luciferase is trapped in large aggregates. Indeed, because we see no reactivation of luciferase by the Hsp70 and Hsp40 control, we can be certain that (1) luciferase is predominantly trapped in large aggregated structures and (2) Skd3 or Hsp104, Hsp70, and Hsp40 disaggregate and reactivate luciferase trapped in these large aggregated structures. Thus, Skd3 or Hsp104, Hsp70, and Hsp40 activity in this assay cannot be explained by simple chaperone (i.e. inhibition of aggregation) activity or simple refolding of misfolded monomeric luciferase. Rather, reactivated luciferase was recovered by disaggregation from large aggregates. We now emphasize this point in the subsection “Skd3 couples ATP hydrolysis to protein disaggregation and reactivation”.</p><disp-quote content-type="editor-comment"><p>(The solubilization of α-synuclein in Figure 4 is insufficient to demonstrate such an activity because the experiments never start with the isolated fibrils only and no equivalent experiments are shown with luciferase).</p></disp-quote><p>The solubilization of a-synuclein fibrils shown in Figure 4 does in fact begin with isolated a-synuclein fibrils, which are devoid of soluble a-synuclein. That is, these samples are comprised of purely α-synuclein fibrils (assembled for 5 days at 37°C with agitation) and do not contain any soluble a-synuclein. We now clarify this point in the subsection “PARL-activated Skd3 dissolves α-synuclein fibrils”. The α-synuclein fibrils were acquired from Kelvin Luk’s lab (Luk et al., 2012). These α-synuclein fibrils have been characterized via electron microscopy and sedimentation assays to be large, fibrillar assemblies that drive thioflavin-S positive, Lewy body-like pathology and contingent neurodegeneration in mice (whereas monomeric α-synuclein does not) (Luk et al., 2012). Thus, they are a disease-causing entity. Furthermore, these a-synuclein fibrils react with thioflavin-T (an amyloid-diagnostic dye) in vitro and no soluble a-synuclein is present in the supernatant in the absence of ATP (no ATP buffer control) (Figure 4). Given that significantly more soluble a-synuclein was observed after Skd3 treatment compared to controls, this observation supports the conclusion that Skd3 disaggregates pre-formed α-synuclein fibrils and thus is a potent protein disaggregase.</p><disp-quote content-type="editor-comment"><p>An in vitro test for disaggregation activity (e.g., spinning down and quantifying aggregates as a function of Skd3 activity) is necessary to validate the primary point of the manuscript.</p></disp-quote><p>As noted above, we have provided these data for a-synuclein (Figure 4). Thus, we quantify the amount of soluble a-synuclein in the supernatant fraction after preformed a-synuclein fibrils are treated with Skd3. Our findings establish that Skd3 is able to liberate soluble forms of a-synuclein from preformed a-synuclein fibrils. In future studies, it will be of interest to pursue sedimentation-based assays of luciferase disaggregation (although as noted above, the recovery of reactivated luciferase is an accurate proxy for disaggregation under our specific assay conditions) or disaggregation of native Skd3 substrates (e.g. HAX1) in vitro to further validate Skd3 as a potent protein disaggregase.</p><disp-quote content-type="editor-comment"><p>2) Similar to (1), the authors should show that Skd3 is able to disaggregate proteins in vivo (the increased solubility of HAX1 in Figure 7 is insufficient to demonstrate such an activity because it cannot distinguish between whether Skd3 resolves aggregation or prevents aggregation from happening in the first place). One approach that might be of use is that of Janowsky et al., who showed that mitochondrial Hsp78 was to induce thermal aggregation of an imported protein in purified mitochondria and then monitor disaggregation +/- Hsp78 (von Janowsky et al., 2006). Other work by Liberek provides some alternative approaches.</p></disp-quote><p>The reviewers raise a good point. Our cell-based studies demonstrate the insolubility of specific substrates in the intermembrane space in the absence of Skd3. These data are highly consistent with Skd3 functioning as a protein disaggregase in vivo. However, they do not exclude the possibility that Skd3 might also function as a chaperone that prevents protein aggregation. In the text, we have been careful to discuss the effect of Skd3 on proteins in the cell as “changes in solubility” in the presence or absence of Skd3. We hope that our careful discussion sufficiently emphasizes the limitations of our experiments. Regardless, our findings establish a critical role for Skd3 in maintaining proteostasis in the mitochondrial intermembrane space.</p><p>In future studies, it will be of interest to assess Skd3 disaggregase activity in vivo using the approaches suggested by the reviewers. Indeed, experiments inspired by the work of Janowsky et al. would help to establish Skd3 disaggregase activity in vivo (Janowsky et al., 2006). Nevertheless, our findings strongly suggest that Skd3 is essential to maintain proteostasis in the mitochondrial intermembrane space and are highly consistent with Skd3 functioning as a protein disaggregase (which it can in vitro).</p><disp-quote content-type="editor-comment"><p>3) The changes in mitochondrial protein solubility observed in SKD3 knockout cells could be caused by loss of SKD3 disaggregase activity on specific proteins or secondary defects in protein import or membrane integration leading to accumulation of misfolded/uninserted proteins in the IMS. The authors should address this question in the Discussion.</p></disp-quote><p>The reviewers raise a good point. A section has been added to the Discussion to address these alternative explanations. It is possible that the changes in protein solubility are partially due to indirect effects of Skd3 on protein import into mitochondria or via sorting of membrane-targeted cargoes. We speculate that Skd3 might also play a role in protein import into mitochondria and further propose that Skd3 may play a role in maintaining the solubility of aggregation-prone mitochondrial targeting signals and membrane proteins during import and sorting (Endo et al., 1995; Poveda-Huertes et al., 2020; Yano et al., 2003). Nonetheless, our in vitro data strongly suggest that Skd3 can function as a potent protein disaggregase, and we suggest that it is likely to function in a similar manner in vivo. Indeed, Skd3 disaggregase activity is likely essential when proteins aggregate in the intermembrane space.</p><disp-quote content-type="editor-comment"><p>4) The loss of ATPase and disaggregase activity seen for the isolated NBD domain (SKD3NBD) could be explained by disassembly of SKD3 hexamers in the absence of the ankyrin domains. The authors should include information on whether these constructs form stable hexamers.</p></disp-quote><p>The reviewers raise an interesting point. We think it is likely that a lack of oligomerization of the isolated NBD domain contributes to the lack of ATPase activity. Previous studies highlighted in the text show that isolated NBD2 constructs of bacterial ClpB form dimers and monomers in vitro and are deficient for ATPase activity (Beinker et al., 2005). Indeed, size-exclusion traces from the purification of isolated Skd3 NBD shows what appears to be a primarily dimeric species. Further studies using SEC-MALS and DLS will be very useful in quantifying this observation. Added emphasis on this point has been made in the Results section of the text (subsection “Skd3 disaggregase activity requires the ankyrin-repeat domain and NBD”).</p><disp-quote content-type="editor-comment"><p>5) Figures 2C/E and 3C/E: Instead of normalized data, it is important to show the real reactivation data. Are 1% or 50% of luciferase molecules reactivatable with Skd3 in this set up?</p></disp-quote><p>The reviewers make a valuable point, which helps to strengthens the data presented in the manuscript. We have reanalyzed the data using a native luciferase standard curve for Figures 2C, E, 3C, E, and Figure 3—figure supplement 2D. In Figure 2C, Buffer alone had 0.04 ± 0.00% (± SEM) native luciferase activity, Hsp70 + Hsp40 reactivated 0.05 ± 0.00%, Hsp104 reactivated 0.08 ± 0.01%, Hsp104 + Hsp70 + Hsp40 reactivated 7.68 ± 0.44%, <sub>MPP</sub>Skd3 reactivated 2.87 ± 0.17%, and <sub>MPP</sub>Skd3 (no ATP) reactivated 0.04 ± 0.00%.</p><p>In Figure 2E, Buffer alone had 0.01 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.02 ± 0.00%, Hsp104 reactivated 0.05 ± 0.00%, Hsp104 + Hsp70 + Hsp40 reactivated 6.71 ± 0.63%, <sub>MPP</sub>Skd3 reactivated 2.45± 0.32%, <sub>MPP</sub>Skd3<sup>K387A</sup> reactivated 0.01 ± 0.00%, <sub>MPP</sub>Skd3<sup>E455Q</sup> reactivated 0.01± 0.00%, and <sub>MPP</sub>Skd3<sup>Y430A</sup> reactivated 0.01 ± 0.00%.</p><p>In Figure 3C, Buffer alone had 0.02 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.03 ± 0.00%, Hsp104 reactivated 0.04 ± 0.01%, Hsp104 + Hsp70 + Hsp40 reactivated 8.58 ± 1.20%, <sub>MPP</sub>Skd3 reactivated 3.10± 0.44%, <sub>MPP</sub>Skd3 (no ATP) reactivated 0.02 ± 0.00%, <sub>PARL</sub>Skd3 reactivated 44.06± 3.78%, and <sub>PARL</sub>Skd3 (no ATP) reactivated 0.08 ± 0.01%.</p><p>In Figure 3E, Buffer alone had 0.02 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.03 ± 0.00%, Hsp104 reactivated 0.08 ± 0.00%, Hsp104 + Hsp70 + Hsp40 reactivated 16.10 ± 1.66%, <sub>PARL</sub>Skd3 reactivated 38.92± 3.70%, <sub>PARL</sub>Skd3<sup>K387A</sup> reactivated 0.02 ± 0.00%, <sub>PARL</sub>Skd3<sup>E455Q</sup> reactivated 0.05± 0.02%, and <sub>PARL</sub>Skd3<sup>Y430A</sup> reactivated 0.05 ± 0.00%.</p><p>To determine how much luciferase could be recovered using higher concentrations of <sub>PARL</sub>Skd3, we re-analyzed the data from Figure 3—figure supplement 2D. In Figure 3—figure supplement 2D, we found that 1.5µM <sub>PARL</sub>Skd3 was able to reactivate 75.60 ± 8.56% native luciferase and 3.0µM <sub>PARL</sub>Skd3 was able to reactivate 75.83 ± 6.80%. This information has been added to the text to supplement the figures and highlights the capability of Skd3 to disaggregate and reactivate luciferase. These findings also strongly suggest that Skd3 is capable of very effectively rescuing previously aggregated proteins.</p><disp-quote content-type="editor-comment"><p>6) No direct evidence has been presented that the pore-loop Y430 makes direct contact with the substrate, hence it seems an overreach to claim that the conserved tyrosine binds the substrate. This statement should be qualified or better supported.</p></disp-quote><p>The subsection “Skd3 couples ATP hydrolysis to protein disaggregation and reactivation” has been amended to qualify the statement and does not directly imply substrate contact from the pore loops. Rather, it frames them as pore-loop contacts and states that these residues are pivotal for translocating substrate in other HCLR clade AAA+ proteins (DeSantis et al., 2012; Gates et al., 2017; Lopez et al., 2020; Martin et al., 2008; Rizo et al., 2019). This issue has been corrected in the Results, Discussion, and legend for Figures 2 and 3.</p><disp-quote content-type="editor-comment"><p>7) Some additional mutants should be tested before concluding that disaggregase activity correlates with disease severity (a term that needs to be defined). Otherwise, this claim should be toned down.</p></disp-quote><p>The subsection “MGCA7-linked Skd3 variants display diminished disaggregase activity” has been modified with a short summary of the scoring system from the literature that defines the clinical severity of the disease (Pronicka et al., 2017). The experiments to test more 3-methylglutaconic aciduria, type VII (MGCA7)-linked variants were in progress. Unfortunately, due to COVID-19 they are now on hold. It will also be valuable in future studies to determine the effect of other MGCA7-linked mutations on Skd3 activity, both in vitro and in cells. Nonetheless, we have assessed the disaggregase and ATPase activity of four MGCA7-linked Skd3 variants and find that disaggregase activity is a better predictor of disease severity than ATPase activity.</p><disp-quote content-type="editor-comment"><p>Updated Essential revisions in light of COVID-19:</p><p>1) Please address as many points as possible raised in the original summary.</p></disp-quote><p>Please see above.</p><disp-quote content-type="editor-comment"><p>2) Regarding Essential revision #1, above – the in vitro data can be strengthened by improved data analysis and discussion of the limitations, which should be possible without additional experiments. Specifically, the amount of luciferase as a % of total activity prior to aggregation should be reported to help support the idea that Skd3 is a robust disaggregase. Please also comment on the estimated fraction of α-synuclein present in fibrils in at the start of the in vitro disaggregation assay.</p></disp-quote><p>We discuss the controls and validation of the luciferase assays in Essential revision #1, which demonstrate that this assay accurately reports on disaggregase activity. In Essential revision #5, we quantify luciferase reactivation as % native luciferase activity and have added this information to supplement the figures in the text of the manuscript. We briefly summarize the analysis here: <sub>MPP</sub>Skd3 can recover ~3% native luciferase activity from the aggregates, <sub>PARL</sub>Skd3 can recover ~44% native luciferase activity from the aggregates and remarkably at higher concentrations, can recover ~75% native activity, which further supports the evidence of Skd3 possessing robust protein-disaggregase activity.</p><p>As noted in Essential revision #1, the α-synuclein fibrils are devoid of soluble a-synuclein. Indeed, there is negligible monomeric α-synuclein present and the sample is virtually 100% fibrillar α-synuclein. For example, there is virtually no signal in the supernatant in the no ATP buffer control (Figure 4).</p><disp-quote content-type="editor-comment"><p>3) Regarding Essential revision #2, above – the fact that the in vivo experiments in Figure 7 do not distinguish between disaggregation and maintaining protein solubility should be directly addressed in the Discussion.</p></disp-quote><p>This topic has been addressed above under Essential revision #2 and corrected in the text.</p></body></sub-article></article>